BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507-539. [PMID: 17256718 DOI: 10.1002/hep.21513] [Cited by in Crossref: 1675] [Cited by in F6Publishing: 1543] [Article Influence: 111.7] [Reference Citation Analysis]
Number Citing Articles
1 Perrillo RP. Hepatitis B surface antigen quantification as a current-day paradox: Obtaining the gold in the face of diminishing returns. Hepatology 2009;49:1063-5. [DOI: 10.1002/hep.22932] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
2 Si Ahmed SN, Zoulim F. Pathobiology of HBV mutants and clinical impact for treatment monitoring. Expert Review of Anti-infective Therapy 2014;7:309-20. [DOI: 10.1586/eri.09.10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
3 Russo MW. Current concepts in the evaluation of patients for liver transplantation. Expert Review of Gastroenterology & Hepatology 2014;1:307-20. [DOI: 10.1586/17474124.1.2.307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Malmström S, Eilard A, Larsson SB, Hannoun C, Norkrans G, Lindh M. Genotype impact on long-term virological outcome of chronic hepatitis B virus infection. Journal of Clinical Virology 2012;54:321-6. [DOI: 10.1016/j.jcv.2012.04.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
5 Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical Gastroenterology and Hepatology 2015;13:2071-2087.e16. [DOI: 10.1016/j.cgh.2015.07.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 10.4] [Reference Citation Analysis]
6 Cotler SJ, Dhamija MK, Siqueira F, Bartram AH, Luc BJ, Layden TJ, Wong SS. Hepatitis B seroprevalence and disease characteristics in an urban Chinatown community. Clin Gastroenterol Hepatol 2009;7:776-80. [PMID: 19344787 DOI: 10.1016/j.cgh.2009.03.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
7 Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol. 2009;51:1091-1096. [PMID: 19836097 DOI: 10.1016/j.jhep.2009.07.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, Aberg JA. Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort. J Acquir Immune Defic Syndr 2014;66:172-80. [PMID: 24694927 DOI: 10.1097/QAI.0000000000000149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
9 Hofmann WP, Soriano V, Zeuzem S. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. Handb Exp Pharmacol 2009;:321-46. [PMID: 19048206 DOI: 10.1007/978-3-540-79086-0_12] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
10 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 324] [Article Influence: 23.0] [Reference Citation Analysis]
11 Fuentes Olmo J, Uribarrena Amézaga R. [Current treatment of hepatitis B infection: where do the new nucleos(t)ide analogues fit in?]. Gastroenterol Hepatol 2011;34:492-503. [PMID: 21550145 DOI: 10.1016/j.gastrohep.2011.02.009] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Zhang HW, Yin JH, Li YT, Li CZ, Ren H, Gu CY, Wu HY, Liang XS, Zhang P, Zhao JF. Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China. Gut. 2008;57:1713-1720. [PMID: 18755887 DOI: 10.1136/gut.2008.157149] [Cited by in Crossref: 81] [Cited by in F6Publishing: 86] [Article Influence: 5.8] [Reference Citation Analysis]
13 Chen S, Huang H. Clinical Non-invasive Model to Predict Liver Inflammation in Chronic Hepatitis B With Alanine Aminotransferase ≤ 2 Upper Limit of Normal. Front Med (Lausanne) 2021;8:661725. [PMID: 34150800 DOI: 10.3389/fmed.2021.661725] [Reference Citation Analysis]
14 Takaki A, Kawano S, Uchida D, Takahara M, Hiraoka S, Okada H. Paradoxical Roles of Oxidative Stress Response in the Digestive System before and after Carcinogenesis. Cancers (Basel) 2019;11:E213. [PMID: 30781816 DOI: 10.3390/cancers11020213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
15 Garbuglia AR, Angeletti C, Lauria FN, Zaccaro P, Cocca AM, Pisciotta M, Solmone M, Capobianchi MR. Comparison of Versant HBV DNA 3.0 and COBAS AmpliPrep-COBAS TaqMan assays for hepatitis B DNA quantitation: Possible clinical implications. J Virol Methods 2007;146:274-80. [PMID: 17707918 DOI: 10.1016/j.jviromet.2007.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
16 Chevaliez S, Pawlotsky J. Virological techniques for the diagnosis and monitoring of hepatitis B and C. Annals of Hepatology 2009;8:7-12. [DOI: 10.1016/s1665-2681(19)31804-6] [Cited by in Crossref: 11] [Article Influence: 0.8] [Reference Citation Analysis]
17 Motaparthi K, Stanisic V, Van Voorhees AS, Lebwohl MG, Hsu S. From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis. J Am Acad Dermatol. 2014;70:178-186. [PMID: 24220724 DOI: 10.1016/j.jaad.2013.08.049] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
18 Magalhães MJ, Pedroto I. Hepatitis B Virus Inactive Carriers: Which Follow-up Strategy? GE Port J Gastroenterol 2015;22:47-51. [PMID: 28868373 DOI: 10.1016/j.jpge.2015.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Li G, Zhou Y, Sze DM, Liu C, Zhang Q, Wang Z, Yu H, Chan G, Wu Z, Su S, Hu Y. Active Ingredients and Action Mechanisms of Yi Guan Jian Decoction in Chronic Hepatitis B Patients with Liver Fibrosis. Evid Based Complement Alternat Med 2019;2019:2408126. [PMID: 31565062 DOI: 10.1155/2019/2408126] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Liu SJ, Iqbal K, Shallow S, Speers S, Rizzo E, Gerard K, Poissant T, Klevens RM. Characterization of chronic hepatitis B cases among foreign-born persons in six population-based surveillance sites, United States 2001-2010. J Immigr Minor Health. 2015;17:7-12. [PMID: 24705737 DOI: 10.1007/s10903-014-0012-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
21 Mast EE, Ward JW. Hepatitis B vaccines. Vaccines. Elsevier; 2008. pp. 205-41. [DOI: 10.1016/b978-1-4160-3611-1.50017-9] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
22 Chung KH, Kim W, Kim BG, Lee HY, Jin E, Cho Y, Seo JY, Kim HY, Jung YJ, Kim JW, Jeong JB, Lee KL. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay. Gut Liver. 2015;9:657-664. [PMID: 25717049 DOI: 10.5009/gnl14188] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
23 Vaculovicova M, Smerkova K, Sedlacek J, Vyslouzil J, Hubalek J, Kizek R, Adam V. Integrated chip electrophoresis and magnetic particle isolation used for detection of hepatitis B virus oligonucleotides. Electrophoresis 2013;34:1548-54. [PMID: 23483558 DOI: 10.1002/elps.201200697] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
24 Lampertico P, Viganò M, Facchetti F, Invernizzi F, Aroldi A, Lunghi G, Messa PG, Colombo M. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. Nephrol Dial Transplant. 2011;26:2037-2041. [PMID: 21486869 DOI: 10.1093/ndt/gfr174] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
25 Li H, Chen TW, Li ZL, Zhang XM, Li CJ, Chen XL, Chen GW, Hu JN, Ye YQ. Albumin and magnetic resonance imaging-liver volume to identify hepatitis B-related cirrhosis and esophageal varices. World J Gastroenterol 2015; 21(3): 988-996 [PMID: 25624735 DOI: 10.3748/wjg.v21.i3.988] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
26 Takaki A, Yamamoto K. Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J Hepatol 2015; 7(7): 968-979 [PMID: 25954479 DOI: 10.4254/wjh.v7.i7.968] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 8.3] [Reference Citation Analysis]
27 Coppola N, Tonziello G, Colombatto P, Pisaturo M, Messina V, Moriconi F, Alessio L, Sagnelli C, Cavallone D, Brunetto M, Sagnelli E. Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. J Infect. 2013;67:322-328. [PMID: 23796869 DOI: 10.1016/j.jinf.2013.06.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
28 Lee PH, Lee TY, Chang GC. Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection. Eur J Cancer 2020;130:272-4. [PMID: 32204966 DOI: 10.1016/j.ejca.2020.02.026] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Ucar F, Sezer S, Ginis Z, Ozturk G, Albayrak A, Basar O, Ekiz F, Coban S, Yuksel O, Armutcu F, Akbal E. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. Eur J Gastroenterol Hepatol. 2013;25:1076-1081. [PMID: 23510962 DOI: 10.1097/meg.0b013e32835fd699] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 6.6] [Reference Citation Analysis]
30 Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015;21:1020-6. [PMID: 26163105 DOI: 10.1016/j.cmi.2015.06.028] [Cited by in Crossref: 53] [Cited by in F6Publishing: 39] [Article Influence: 7.6] [Reference Citation Analysis]
31 Lee HJ, Seo YS, Kim DJ, Kang HS, An H, Kim JH, Cheong JY, Yim HJ, Yeon JE, Lee HS, Byun KS, Cho SW, Kim DJ, Um SH, Kim CD, Ryu HS. Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B: HALF index in chronic hepatitis B patients. Journal of Gastroenterology and Hepatology 2011;26:987-95. [DOI: 10.1111/j.1440-1746.2010.06609.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
32 Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672-686. [PMID: 25759099 DOI: 10.1016/j.virol.2015.02.031] [Cited by in Crossref: 398] [Cited by in F6Publishing: 381] [Article Influence: 56.9] [Reference Citation Analysis]
33 Gish RG, Locarnini S. Genotyping and genomic sequencing in clinical practice. Clin Liver Dis 2007;11:761-95, viii. [PMID: 17981228 DOI: 10.1016/j.cld.2007.08.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
34 Perumalswami PV, Factor SH, Kapelusznik L, Friedman SL, Pan CQ, Chang C, Di Clemente F, Dieterich DT. Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol. 2013;58:890-897. [PMID: 23333446 DOI: 10.1016/j.jhep.2013.01.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
35 Idris BI, Brosa M, Richardus JH, Esteban R, Schalm SW, Buti M. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain: . European Journal of Gastroenterology & Hepatology 2008;20:320-6. [DOI: 10.1097/meg.0b013e3282f340c8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
36 Li M, Sun XH, Zhu XJ, Jin SG, Zeng ZJ, Zhou ZH, Yu Z, Gao YQ. HBcAg induces PD-1 upregulation on CD4+T cells through activation of JNK, ERK and PI3K/AKT pathways in chronic hepatitis-B-infected patients. Lab Invest. 2012;92:295-304. [PMID: 22042085 DOI: 10.1038/labinvest.2011.157] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
37 van der Veen YJJ, van Empelen P, de Zwart O, Visser H, Mackenbach JP, Richardus JH. Cultural tailoring to promote hepatitis B screening in Turkish Dutch: a randomized control study. Health Promotion International 2014;29:692-704. [DOI: 10.1093/heapro/dat020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
38 Schiff E, Simsek H, Lee WM, Chao YC, Sette H Jr, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol. 2008;103:2776-2783. [PMID: 18721244 DOI: 10.1111/j.1572-0241.2008.02086.x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 6.1] [Reference Citation Analysis]
39 Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36:1188-1194. [PMID: 19447932 DOI: 10.3899/jrheum.081246] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
40 Liu T, Sun Y, Zhou J, Yang F, Zou X, Wang L, Wu X, Chen Y, Piao H, Lu L, Jiang W, Xu Y, Feng B, Nan Y, Xie W, Chen G, Zheng H, Li H, Ding H, Liu H, Wang T, Ou X, Wu S, Kong Y, Wang P, Cong M, Zhang Y, You H, Jia J. On-treatment changes of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein are associated with the regression of liver fibrosis in chronic hepatitis B patients on interferon α add-on therapy. J Med Virol 2019;91:1499-509. [PMID: 30905065 DOI: 10.1002/jmv.25465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
41 Li SY, Qin L, Zhang L, Song XB, Zhou Y, Zhou J, Lu XJ, Cao J, Wang LL, Wang J. Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China. Med Sci Monit. 2011;17:PH75-PH80. [PMID: 21959623 DOI: 10.12659/msm.881965] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
42 Viganò M, Mangia G, Lampertico P. Results of Treatment of Chronic Hepatitis B with Pegylated Interferon. Clinics in Liver Disease 2013;17:425-43. [DOI: 10.1016/j.cld.2013.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
43 Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J;  FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol. 2017;67:918-924. [PMID: 28736139 DOI: 10.1016/j.jhep.2017.07.012] [Cited by in Crossref: 118] [Cited by in F6Publishing: 104] [Article Influence: 23.6] [Reference Citation Analysis]
44 Fournier C, Zoulim F. Antiviral therapy of chronic hepatitis B: prevention of drug resistance. Clin Liver Dis. 2007;11:869-892, ix. [PMID: 17981233 DOI: 10.1016/j.cld.2007.08.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
45 Béguelin C, Fall F, Seydi M, Wandeler G. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. Expert Rev Gastroenterol Hepatol 2018;12:537-46. [PMID: 29737218 DOI: 10.1080/17474124.2018.1474097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
46 Jain S, Su YH, Su YP, McCloud S, Xue R, Lee TJ, Lin SC, Lin SY, Song W, Steffen JD, Hu CT. Characterization of the hepatitis B virus DNA detected in urine of chronic hepatitis B patients. BMC Gastroenterol 2018;18:40. [PMID: 29548283 DOI: 10.1186/s12876-018-0767-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. J Dig Dis. 2013;14:446-450. [PMID: 23615131 DOI: 10.1111/1751-2980.12065] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
48 Jung YK, Yeon JE, Lee KG, Jung ES, Kim JH, Kim JH, Seo YS, Yim HJ, Um SH, Ryu HS. Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients. Korean J Hepatol. 2011;17:261-267. [PMID: 22310790 DOI: 10.3350/kjhep.2011.17.4.261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
49 Triolo M, Della Corte C, Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. Liver Int. 2014;34 Suppl 1:139-145. [PMID: 24373091 DOI: 10.1111/liv.12394] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
50 Liu C, Chen P, Chen D, Kao J. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int 2013;7:316-26. [DOI: 10.1007/s12072-011-9279-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
51 Zhang QQ, An X, Liu YH, Li SY, Zhong Q, Wang J, Hu HD, Zhang DZ, Ren H, Hu P. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J. 2011;8:72. [PMID: 21324130 DOI: 10.1186/1743-422x-8-72] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
52 Yao K, Wang J, Wang L, Xia J, Yan X, Wu W, Liu J, Wang L, Yin S, Tong X, Ding W, Huang R, Wu C. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J Med Virol 2021. [PMID: 34499353 DOI: 10.1002/jmv.27327] [Reference Citation Analysis]
53 Pei SN, Chen CH. Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab. Leuk Lymphoma 2015;56:1611-8. [PMID: 25248874 DOI: 10.3109/10428194.2014.964699] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
54 Vermehren J, Kau A, Zeuzem S. Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment. Curr Hepatitis Rep 2010;9:53-9. [DOI: 10.1007/s11901-010-0036-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
56 Martin CM, Welge JA, Shire NJ, Rouster SD, Shata MT, Sherman KE, Blackard JT. Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals. J Viral Hepat. 2010;17:588-597. [PMID: 19889143 DOI: 10.1111/j.1365-2893.2009.01214.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
57 Makara M, Horváth G, Gervain J, Pár A, Szalay F, Telegdy L, Tornai I, Újhelyi E, Hunyady B. Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis. Orvosi Hetilap 2012;153:375-94. [DOI: 10.1556/oh.2012.29338] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
58 Nishida T, Matsubara T, Yakushijin T, Inada M. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. Hepatol Int 2019;13:407-15. [PMID: 31290069 DOI: 10.1007/s12072-019-09966-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
59 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother 2013;57:6325-32. [PMID: 24100506 DOI: 10.1128/AAC.01742-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
60 Almasio PL, Babudieri S, Barbarini G, Brunetto M, Conte D, Dentico P, Gaeta GB, Leonardi C, Levrero M, Mazzotta F, Morrone A, Nosotti L, Prati D, Rapicetta M, Sagnelli E, Scotto G, Starnini G. Recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B and C in special population groups (migrants, intravenous drug users and prison inmates). Digestive and Liver Disease 2011;43:589-95. [DOI: 10.1016/j.dld.2010.12.004] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.3] [Reference Citation Analysis]
61 Ning LH, Hao J, Liao ZL, Zhou YY, Guo H, Zhao XY. A survey on the current trends in the management of hepatitis B in China. Eur J Gastroenterol Hepatol. 2012;24:884-889. [PMID: 22569081 DOI: 10.1097/meg.0b013e32835447fa] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
62 Laws PM, Young HS. Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol 2010;3:25-37. [PMID: 21437057 DOI: 10.2147/ccid.s6497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
63 Zhi X, Liu Q, Zhang X, Zhang Y, Feng J, Cui D. Quick genotyping detection of HBV by giant magnetoresistive biochip combined with PCR and line probe assay. Lab Chip 2012;12:741. [DOI: 10.1039/c2lc20949g] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
64 Chen LP, Zhao J, Du Y, Han YF, Su T, Zhang HW, Cao GW. Antiviral treatment to prevent chronic hepatitis B or C-related hepatocellular carcinoma. World J Virol 2012; 1(6): 174-183 [PMID: 24175223 DOI: 10.5501/wjv.v1.i6.174] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
65 Akbar SM, Hiasa Y, Mishiro S, Onji M. Treatment of hepatitis B virus-infected patients: utility of therapeutic recommendations in developing countries. Expert Opin Pharmacother 2009;10:1605-14. [PMID: 19496738 DOI: 10.1517/14656560903005579] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
66 Hasosah MY, Ghandourah HS, Alsahafi AF, Sukkar GA, Jacobson K. Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B. Saudi J Gastroenterol 2012;18:217-20. [PMID: 22626803 DOI: 10.4103/1319-3767.96465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
67 Malik R, Kennedy P, Suri D, Brown A, Goldin R, Main J, Thomas H, Thursz M. The role of liver fibrosis assessment in the management of patients with chronic hepatitis B infection: lessons learned from a single centre experience. Hepat Res Treat 2011;2011:524027. [PMID: 22114737 DOI: 10.1155/2011/524027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
68 Gong X, Yang J, Tang J, Gu C, Huang L, Zheng Y, Liang H, Wang M, Wu C, Chen Y. A Mechanistic Assessment of the Discordance between Normal Serum Alanine Aminotransferase Levels and Altered Liver Histology in Chronic Hepatitis B. PLoS One. 2015;10:e0134532. [PMID: 26230094 DOI: 10.1371/journal.pone.0134532] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
69 Picchio CA, Lens S, Hernandez-Guerra M, Arenas J, Andrade RJ, Crespo J, García-Samaniego J, Romero-Gómez M, Turnes J, Calleja JL, Simón MÁ, White TM, Riveiro-Barciela M, Pocurull A, Morales-Arraez D, Gómez A, Buti M, Lazarus JV. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. Sci Rep 2021;11:24133. [PMID: 34921156 DOI: 10.1038/s41598-021-01885-0] [Reference Citation Analysis]
70 Zoulim F. [Current data on the treatment of chronic hepatitis B]. Presse Med 2008;37:287-93. [PMID: 18042341 DOI: 10.1016/j.lpm.2007.06.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat 2016;23:545-59. [PMID: 27028545 DOI: 10.1111/jvh.12519] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
72 Tong MJ, Trieu J. Hepatitis B inactive carriers: clinical course and outcomes. J Dig Dis. 2013;14:311-317. [PMID: 23433008 DOI: 10.1111/1751-2980.12051] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
73 Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol. 2012;36:84-93. [PMID: 21920838 DOI: 10.1016/j.clinre.2011.07.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
74 Hoa PT, Huy NT, Thu le T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K. Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2009;53:5134-5140. [PMID: 19770281 DOI: 10.1128/aac.00276-09] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
75 Montagnani M, Giandinoto M, Lisotti A, Galli S, Azzaroli F, Buonfiglioli F, Turco L, Aldini R, Mazzella G. High dose lamivudine in HBV-related cirrhotic patients with unsatisfactory response after adefovir add-on. Dig Dis Sci 2012;57:561-7. [PMID: 21881973 DOI: 10.1007/s10620-011-1873-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Cai CJ, Lu MQ, Chen YH, Zhao H, Li MR, Chen GH. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant. 2012;26:208-215. [PMID: 21981656 DOI: 10.1111/j.1399-0012.2011.01448.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
77 Gong Y, Zhao C, Zhao P, Wang M, Zhou G, Han F, Cui Y, Qian J, Zhang H, Xiong H. Role of IL-10-Producing Regulatory B Cells in Chronic Hepatitis B Virus Infection. Dig Dis Sci. 2015;60:1308-1314. [PMID: 25260658 DOI: 10.1007/s10620-014-3358-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
78 Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1059-1068. [PMID: 20807216 DOI: 10.1111/j.1365-2036.2010.04447.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
79 Yang H, Sherman M, Su J, Chen P, Liaw Y, Iloeje UH, Chen C. Nomograms for Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection. JCO 2010;28:2437-44. [DOI: 10.1200/jco.2009.27.4456] [Cited by in Crossref: 177] [Cited by in F6Publishing: 77] [Article Influence: 14.8] [Reference Citation Analysis]
80 Sohn W, Paik YH, Cho JY, Ahn JM, Choi GS, Kim JM, Kwon CH, Joh JW, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load. J Viral Hepat 2015;22:539-50. [PMID: 25377516 DOI: 10.1111/jvh.12356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
81 Yazdany J, Calabrese L. Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines? Arthritis Care Res (Hoboken) 2010;62:585-9. [PMID: 20191573 DOI: 10.1002/acr.20167] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
82 Leonard AN, Love BL, Norris LB, Siddiqui SK, Wallam MN, Bennett CL. Screening for viral hepatitis prior to rituximab chemotherapy. Ann Hematol 2016;95:27-33. [PMID: 26382277 DOI: 10.1007/s00277-015-2502-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
83 Qiu L, Chen L, Chen K. Antihepatitis B therapy: a review of current medications and novel small molecule inhibitors. Fundam Clin Pharmacol 2014;28:364-81. [DOI: 10.1111/fcp.12053] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
84 Borgniet O, Parvaz P, Bouix C, Chevallier P, Trépo C, André P, Zoulim F. Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B. J Med Virol. 2009;81:1336-1342. [PMID: 19551826 DOI: 10.1002/jmv.21519] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
85 Giacchino R, Cappelli B. Treatment of viral hepatitis B in children. Expert Opinion on Pharmacotherapy 2010;11:889-903. [DOI: 10.1517/14656561003642006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
86 Chan S, Yuen JW, Gohel MI, Chung C, Wong H, Kwong KK. Guasha-induced hepatoprotection in chronic active hepatitis B: A case study. Clinica Chimica Acta 2011;412:1686-8. [DOI: 10.1016/j.cca.2011.05.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
87 Lu Y, Wu Z, Peng Q, Ma L, Zhang X, Zhao J, Qin X, Li S. Role of IL-4 gene polymorphisms in HBV-related hepatocellular carcinoma in a Chinese population. PLoS One. 2014;9:e110061. [PMID: 25295591 DOI: 10.1371/journal.pone.0110061] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
88 Ling WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013;108:1931-1935. [PMID: 23652302 DOI: 10.1038/bjc.2013.225] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
89 McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int. 2009;3:334-342. [PMID: 19669359 DOI: 10.1007/s12072-008-9112-z] [Cited by in Crossref: 155] [Cited by in F6Publishing: 145] [Article Influence: 11.1] [Reference Citation Analysis]
90 Yang J, Chen J, He J, Xie Y, Zhu Y, Cao H, Li L. Profiling the repertoire of T-cell receptor beta-chain variable genes in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection. Cell Mol Immunol 2014;11:332-42. [PMID: 25126662 DOI: 10.1038/cmi.2014.22] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
91 Wang J, Ma K, Han M, Guo W, Huang J, Yang D, Zhao X, Song J, Tian D, Qi J, Huang Y, Ning Q. Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model. Hepatol Int 2014;8:64-71. [PMID: 26202407 DOI: 10.1007/s12072-013-9485-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
92 Wu DX, Fu XY, Gong GZ, Sun KW, Gong HY, Wang L, Wu J, Tan DM. Novel HBV mutations and their value in predicting efficacy of conventional interferon. Hepatobiliary Pancreat Dis Int 2017;16:189-96. [PMID: 28381384 DOI: 10.1016/s1499-3872(16)60184-4] [Reference Citation Analysis]
93 Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, Kuo SF, Liu CH, Chen PJ, Chen DS, Kao JH. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140-1149.e3; quiz e13-14. [PMID: 22333950 DOI: 10.1053/j.gastro.2012.02.007] [Cited by in Crossref: 307] [Cited by in F6Publishing: 295] [Article Influence: 30.7] [Reference Citation Analysis]
94 Kim MH, Kim K, Lee JS, Lee HW, Kim HJ, Yun SG, Kim N, Bae WK, Moon YS. Efficacy of 48-week clevudine therapy for chronic hepatitis B. Korean J Hepatol 2009;15:331. [DOI: 10.3350/kjhep.2009.15.3.331] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
95 Kim YJ, Kim HY, Kim JS, Lee JH, Yoon JH, Kim CY, Park BL, Cheong HS, Bae JS, Kim S, Shin HD, Lee HS. Putative association of transforming growth factor-alpha polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Viral Hepat 2010;17:518-26. [PMID: 19780938 DOI: 10.1111/j.1365-2893.2009.01205.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
96 Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV;  GLOBE Study Group. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-495. [PMID: 19027013 DOI: 10.1053/j.gastro.2008.10.026] [Cited by in Crossref: 412] [Cited by in F6Publishing: 394] [Article Influence: 29.4] [Reference Citation Analysis]
97 Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology. 2009;49:S61-S71. [PMID: 19399798 DOI: 10.1002/hep.22930] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
98 Lunel-Fabiani F, Masson C, Ducancelle A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint Bone Spine. 2014;81:478-484. [PMID: 24561021 DOI: 10.1016/j.jbspin.2014.01.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
99 Farag MM, Peschel G, Müller M, Weigand K. Characterization Of The Interaction Between Subviral Particles Of Hepatitis B Virus And Dendritic Cells - In Vitro Study. Infect Drug Resist 2019;12:3125-35. [PMID: 31632101 DOI: 10.2147/IDR.S221294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
100 Spradling PR, Xing J, Rupp LB, Moorman AC, Gordon SC, Teshale ET, Lu M, Boscarino JA, Schmidt MA, Trinacty CM, Holmberg SD; Chronic Hepatitis Cohort Study Investigators. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013. Aliment Pharmacol Ther. 2016;44:1080-1089. [PMID: 27640985 DOI: 10.1111/apt.13802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
101 Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008;47:e52-e56. [PMID: 18643758 DOI: 10.1086/590968] [Cited by in Crossref: 114] [Cited by in F6Publishing: 91] [Article Influence: 8.8] [Reference Citation Analysis]
102 Nguyen K, Van Nguyen T, Shen D, Xia V, Tran D, Banh K, Ruan V, Hu K. Prevalence and Presentation of Hepatitis B and C Virus (HBV and HCV) Infection in Vietnamese Americans via Serial Community Serologic Testing. J Immigrant Minority Health 2015;17:13-20. [DOI: 10.1007/s10903-013-9975-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
103 Pol S, Vallet-pichard A. Hépatite chronique B : situations rares : dialyse, transplantation rénale et traitements pré-emptifs en situation d’immunosuppression. Gastroentérologie Clinique et Biologique 2008;32:S34-41. [DOI: 10.1016/s0399-8320(08)73263-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
104 Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ, Marrero JA, Licari T, Lok AS. Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology. 2011;53:1854-1863. [PMID: 21618260 DOI: 10.1002/hep.24318] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 8.5] [Reference Citation Analysis]
105 Tatsukawa M, Takaki A, Shiraha H, Koike K, Iwasaki Y, Kobashi H, Fujioka S, Sakaguchi K, Yamamoto K. Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients. BMC Cancer 2011;11:458. [PMID: 22014121 DOI: 10.1186/1471-2407-11-458] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
106 Cooksley WG. Do we need to determine viral genotype in treating chronic hepatitis B? J Viral Hepat. 2010;17:601-610. [PMID: 20529201 DOI: 10.1111/j.1365-2893.2010.01326.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
107 Gogoi D, Borkakoty B, Biswas D, Mahanta J. Activation and Exhaustion of Adaptive Immune Cells in Hepatitis B Infection. Viral Immunol 2015;28:348-53. [PMID: 26331345 DOI: 10.1089/vim.2014.0115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
108 Schilsky ML. Hepatitis B "360". Transplant Proc 2013;45:982-5. [PMID: 23622604 DOI: 10.1016/j.transproceed.2013.02.099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
109 Pisaturo M, Di Caprio G, Calò F, Portunato F, Martini S, Coppola N. Management of HBV reactivation in non-oncological patients. Expert Rev Anti Infect Ther 2018;16:611-24. [PMID: 30058401 DOI: 10.1080/14787210.2018.1505501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
110 Hayashi K, Katano Y, Ishigami M, Itoh A, Hirooka Y, Nakano I, Goto H. Successful cessation of lamivudine using interferon in a patient with chronic hepatitis B who received prophylactic lamivudine treatment during chemotherapy. Clin J Gastroenterol 2009;2:210-3. [PMID: 26192298 DOI: 10.1007/s12328-009-0065-0] [Reference Citation Analysis]
111 Cho Y, Lee DH, Chung KH, Jin E, Lee J, Cho EJ, Yu SJ, Kim JW, Jeong SH, Yoon J, Lee H, Kim CY, Kim YJ. The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir. Dig Dis Sci 2013;58:1363-70. [DOI: 10.1007/s10620-012-2480-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
112 Afif W, Loftus EV. Safety profile of IBD therapeutics: infectious risks. Med Clin North Am. 2010;94:115-133. [PMID: 19944801 DOI: 10.1016/j.mcna.2009.08.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
113 Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther. 2010;31:20-34. [PMID: 19681818 DOI: 10.1111/j.1365-2036.2009.04112.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 6.3] [Reference Citation Analysis]
114 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Mashiba T, Hiraoka A, Ochi H, Koizumi Y, Tada F, Hirooka M, Yoshida O, Imai Y, Abe M, Hiasa Y. Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. Hepatol Int. 2016;10:320-327. [PMID: 26198757 DOI: 10.1007/s12072-015-9647-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
115 Vachon M, Perumalswami P, Dieterich DT. Hepatobiliary Manifestations of Human Immunodeficiency Virus. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff's Diseases of the Liver. Oxford: Wiley-Blackwell; 2011. pp. 1060-82. [DOI: 10.1002/9781119950509.ch41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
116 Scott LJ, Keating GM. Entecavir: a review of its use in chronic hepatitis B. Drugs. 2009;69:1003-1033. [PMID: 19496629 DOI: 10.2165/00003495-200969080-00005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
117 Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519-528. [PMID: 18378948 DOI: 10.7326/0003-4819-148-7-200804010-00008] [Cited by in Crossref: 321] [Cited by in F6Publishing: 295] [Article Influence: 22.9] [Reference Citation Analysis]
118 Pollack H, Wang S, Wyatt L, Peng CH, Wan K, Trinh-Shevrin C, Chun K, Tsang T, Kwon S. A comprehensive screening and treatment model for reducing disparities in hepatitis B. Health Aff (Millwood) 2011;30:1974-83. [PMID: 21976342 DOI: 10.1377/hlthaff.2011.0700] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
119 Chen C, Chang M. HEPATITIS B AND PREGNANCY, THE SCIENTIFIC BASIS FOR PERINATAL PREVENTION. Fet Matern Med Rev 2010;21:89-113. [DOI: 10.1017/s0965539510000021] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
120 Lee KS. [Clevudine therapy in patients with chronic hepatitis B]. Korean J Hepatol 2009;15:119-21. [PMID: 19581763 DOI: 10.3350/kjhep.2009.15.2.119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
121 Stroffolini T, Gaeta GB, Mele A. AASLD Practice Guidelines on chronic hepatitis B and HBV infection in Italy. Hepatology. 2007;46:608-609; author reply 609. [PMID: 17661422 DOI: 10.1002/hep.21841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
122 Goto T, Yoshida H, Tateishi R, Enooku K, Goto E, Sato T, Ohki T, Masuzaki R, Imamura J, Shiina S. Influence of serum HBV DNA load on recurrence of hepatocellular carcinoma after treatment with percutaneous radiofrequency ablation. Hepatol Int. 2011;5:767-773. [PMID: 21484129 DOI: 10.1007/s12072-011-9255-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
123 Kim ES, Cho KB, Park KS, Jang BI, Kim KO, Jeon SW, Kim EY, Yang CH, Kim WJ;  Daegugyeongbuk Gastrointestinal Study Group (DGSG). Prevalence of hepatitis-B viral markers in patients with inflammatory bowel disease in a hepatitis-B-endemic area: inadequate protective antibody levels in young patients. J Clin Gastroenterol. 2014;48:553-558. [PMID: 24162170 DOI: 10.1097/01.mcg.0000436435.75392.23] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
124 Viganò M, Lampertico P, Facchetti F, Lunghi G, Colombo M. Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine. J Viral Hepat. 2008;15:922-924. [PMID: 19087228 DOI: 10.1111/j.1365-2893.2008.01047.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
125 Hwang JP, Roundtree AK, Engebretson JC, Suarez-Almazor ME. Medical care of hepatitis B among Asian American populations: perspectives from three provider groups. J Gen Intern Med 2010;25:220-7. [PMID: 20049549 DOI: 10.1007/s11606-009-1204-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
126 Mayer TK, Vargas RL, Knebel AE, Williams SA, Culver SP, Clark DM, King LR. Hepatitis B assays in serum, plasma and whole blood on filter paper. BMC Clin Pathol 2012;12:8. [PMID: 22606954 DOI: 10.1186/1472-6890-12-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
127 You J, Zhuang L, Zhang YF, Chen HY, Sriplung H, Geater A, Chongsuvivatwong V, Piratvisuth T, McNeil E, Yu L, Tang BZ, Huang JH. Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load. World J Gastroenterol 2009; 15(27): 3382-3393 [PMID: 19610139 DOI: 10.3748/wjg.15.3382] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
128 Li R, Zhang X, Ma KS, Li XW, Xia F, Zhong H, Tang CL, Guo Y, Yan XC. Dynamic enhancing vascular pattern of intrahepatic peripheral cholangiocarcinoma on contrast-enhanced ultrasound: the influence of chronic hepatitis and cirrhosis. Abdom Imaging. 2013;38:112-119. [PMID: 22323003 DOI: 10.1007/s00261-012-9854-x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
129 Poggio PD, Zaccanelli M, Oggionni M, Colombo S, Jamoletti C, Puhalo V. Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B. World J Gastroenterol 2007; 13(30): 4096-4099 [PMID: 17696228 DOI: 10.3748/wjg.v13.i30.4096] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
130 Vivekanandan P, Thomas D, Torbenson M. Methylation regulates hepatitis B viral protein expression. J Infect Dis. 2009;199:1286-1291. [PMID: 19301974 DOI: 10.1086/597614] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
131 Moucari R, Mackiewicz V, Lada O, Ripault M, Castelnau C, Martinot-peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-chanoine M, Marcellin P. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7. [DOI: 10.1002/hep.22744] [Cited by in Crossref: 329] [Cited by in F6Publishing: 305] [Article Influence: 23.5] [Reference Citation Analysis]
132 Ahn SH, Kweon YO, Paik SW, Sohn JH, Lee KS, Kim DJ, Piratvisuth T, Yuen MF, Chutaputti A, Chao YC. Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. Hepatol Int. 2011;Oct 12; Epub ahead of print. [PMID: 21989925 DOI: 10.1007/s12072-011-9314-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
133 Fauzyah Y, Ono C, Torii S, Anzai I, Suzuki R, Izumi T, Morioka Y, Maeda Y, Okamoto T, Fukuhara T, Matsuura Y. Ponesimod suppresses hepatitis B virus infection by inhibiting endosome maturation. Antiviral Res 2021;186:104999. [PMID: 33346055 DOI: 10.1016/j.antiviral.2020.104999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Zhu Y, Curtis M, Borroto-esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A–H and its use in antiviral phenotyping assays. Journal of Virological Methods 2011;173:340-6. [DOI: 10.1016/j.jviromet.2011.03.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
135 Jia W, Zhao Y, Li R, Wu Y, Li Z, Gong P. Synthesis and In-Vitro Anti-Hepatitis-B Virus Activity of 6 H -[1]Benzothiopyrano[4,3- b ] quinolin-10-ols. Arch Pharm Chem Life Sci 2009;342:507-12. [DOI: 10.1002/ardp.200900070] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
136 Mello FC, Fernandes CA, Gomes Sde A. Antiviral therapy against chronic hepatitis B in Brazil: high rates of lamivudine resistance mutations and correlation with HBV genotypes. Mem Inst Oswaldo Cruz. 2012;107:317-325. [PMID: 22510826 DOI: 10.1590/S0074-02762012000300005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
137 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Xu Y, Wu XN, Shi YW, Wei W, Yang AT, Sun YM, Zhao WS, You H. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis. Chin Med J (Engl) 2015;128:1867-72. [PMID: 26168824 DOI: 10.4103/0366-6999.160488] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
139 Dufour DR. Alanine aminotransferase: is it healthy to be “normal”? Hepatology. 2009;50:1699-1701. [PMID: 19937679 DOI: 10.1002/hep.23358] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
140 Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17:16-22. [PMID: 19622117 DOI: 10.1111/j.1365-2893.2009.01146.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 7.1] [Reference Citation Analysis]
141 Kim BK, Han KH, Park JY, Ahn SH, Chon CY, Kim JK, Paik YH, Lee KS, Park YN, Kim DY. External validation of P2/MS and comparison with other simple non-invasive indices for predicting liver fibrosis in HBV-infected patients. Dig Dis Sci 2010;55:2636-43. [PMID: 19960253 DOI: 10.1007/s10620-009-1070-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
142 Kanzaki N, Iwane S, Oeda S, Okada M, Kimura H, Eguchi Y, Fujimoto K. Categorization and Characterization of Activities Designed to Help Health-care Professionals Involved in Hepatitis Care Increase Their Awareness of the Disease: The Classification of Hepatitis Medical Care Coordinators. Intern Med 2019;58:1825-34. [PMID: 30799338 DOI: 10.2169/internalmedicine.1755-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
143 Jiang W, Fang YJ, Wu XJ, Wang FL, Lu ZH, Zhang RX, Ding PR, Fan WH, Pan ZZ, De-Sen Wan. Intraoperative blood loss independently predicts survival and recurrence after resection of colorectal cancer liver metastasis. PLoS One 2013;8:e76125. [PMID: 24098431 DOI: 10.1371/journal.pone.0076125] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
144 Santantonio T, Fasano M. Resistance profile of entecavir in patients with chronic hepatitis B. Digestive and Liver Disease Supplements 2008;2:11-5. [DOI: 10.1016/s1594-5804(09)60005-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Nishida T, Kobashi H, Fujioka S, Fujio K, Takaguchi K, Ikeda H, Kawaguchi M, Ando M, Araki Y, Higashi T. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol. 2008;23:794-803. [PMID: 18086120 DOI: 10.1111/j.1440-1746.2007.05240.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
146 Gervain J, Horváth G, Hunyady B, Makara M, Pár A, Szalay F, Tornai I, Telegdy L; Gasztroenterológiai Szakmai Kollégium., Infektológiai Szakmai Kollégium. [Protocol for the antiviral therapy of hepatitis B and D]. Orv Hetil 2010;151:24-8. [PMID: 20031523 DOI: 10.1556/OH.2010.28776] [Reference Citation Analysis]
147 Lee T, Núñez M. Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients. HIV Clin Trials 2009;10:153-9. [PMID: 19632954 DOI: 10.1310/hct1003-153] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
148 Chen YH, de Carvalho HM, Kalyoncu U, Llamado LJQ, Solano G, Pedersen R, Lukina G, Lichauco JJ, Vasilescu RS. Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-α inhibitors in clinical practice. Biologics 2018;12:1-9. [PMID: 29391775 DOI: 10.2147/BTT.S148606] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
149 Williams S, Vally H, Fielding J, Cowie B. Chronic hepatitis B surveillance in Victoria, 1998-2008: instituting a 21st Century approach to an old disease. Australian and New Zealand Journal of Public Health 2011;35:16-21. [DOI: 10.1111/j.1753-6405.2010.00611.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
150 Koktekir BE, Sumer S, Bakbak B, Gedik S, Gonul S, Ural O. Ocular effects of pegylated interferon-α in patients with chronic hepatitis B. Cutan Ocul Toxicol 2013;32:275-8. [PMID: 23477604 DOI: 10.3109/15569527.2013.775656] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
151 Chen H, He G, Chen Y, Zhang X, Wu S. Differential Activation of NLRP3, AIM2, and IFI16 Inflammasomes in Humans with Acute and Chronic Hepatitis B. Viral Immunol 2018;31:639-45. [PMID: 30222506 DOI: 10.1089/vim.2018.0058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
152 Runyon BA. Management of adult patients with ascites due to cirrhosis: An update. Hepatology 2009;50:1321-1321. [DOI: 10.1002/hep.23261] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
153 Chen CH, Hsieh HH, Wu TY. Real-world prevalence of hepatitis B virus reactivation in cancer patients in Taiwan. J Oncol Pharm Pract 2021;27:63-70. [PMID: 32264743 DOI: 10.1177/1078155220913095] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Kim HS, Kim SJ, Park HW, Shin WG, Kim KH, Lee JH, Kim HY, Jang MK. Prevalence and clinical significance of hepatitis D virus co-infection in patients with chronic hepatitis B in Korea. J Med Virol 2011;83:1172-7. [DOI: 10.1002/jmv.22095] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
155 ul Haq N, Hassali MA, Shafie AA, Saleem F, Farooqui M, Haseeb A, Aljadhey H. A cross-sectional assessment of knowledge, attitude and practice among Hepatitis-B patients in Quetta, Pakistan. BMC Public Health. 2013;13:448. [PMID: 23641704 DOI: 10.1186/1471-2458-13-448] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
156 You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Chen HY, Yu L, Tang BZ, Huang JH. Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B. World J Gastroenterol 2008; 14(7): 1112-1119 [PMID: 18286696 DOI: 10.3748/wjg.14.1112] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
157 Mani N, Cole AG, Phelps JR, Ardzinski A, Cobarrubias KD, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Guo H, Guo JT, Harasym TO, Kadhim S, Kultgen SG, Lee ACH, Li AHL, Long Q, Majeski SA, Mao R, McClintock KD, Reid SP, Rijnbrand R, Snead NM, Micolochick Steuer HM, Stever K, Tang S, Wang X, Zhao Q, Sofia MJ. Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation. Antimicrob Agents Chemother. 2018;62:e00082-18. [PMID: 29555628 DOI: 10.1128/aac.00082-18] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
158 Keshvari M, Alavian SM, Sharafi H. How can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level? Hepat Mon 2014;14:e15285. [PMID: 24693309 DOI: 10.5812/hepatmon.15285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
159 Odaibo GN, Ola SO, Olaleye OD. Hepatitis B virus DNA in patients with HBsAg in south western Nigeria. J Med Virol 2013;85:214-8. [PMID: 23161583 DOI: 10.1002/jmv.23418] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
160 Chotiyaputta W, Lok ASF. Endpoints of hepatitis B treatment: Endpoints of HBV treatment. Journal of Viral Hepatitis 2010;17:675-84. [DOI: 10.1111/j.1365-2893.2010.01369.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
161 Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir. Clin Mol Hepatol 2014;20:267-73. [PMID: 25320730 DOI: 10.3350/cmh.2014.20.3.267] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
162 Liu Z, Que S, Xu J, Peng T. Alanine aminotransferase-old biomarker and new concept: a review. Int J Med Sci 2014;11:925-35. [PMID: 25013373 DOI: 10.7150/ijms.8951] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 9.6] [Reference Citation Analysis]
163 Yang F, Wu L, Xu W, Liu Y, Zhen L, Ning G, Song J, Jiao Q, Zheng Y, Chen T, Xie C, Peng L. Diverse Effects of the NTCP p.Ser267Phe Variant on Disease Progression During Chronic HBV Infection and on HBV preS1 Variability. Front Cell Infect Microbiol 2019;9:18. [PMID: 30881922 DOI: 10.3389/fcimb.2019.00018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
164 Parvez MK. HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches. World J Hepatol 2015; 7(1): 121-126 [PMID: 25625003 DOI: 10.4254/wjh.v7.i1.121] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
165 Din ES, Wasley A, Jacques-carroll L, Sirotkin B, Wang S. Estimating the Number of Births to Hepatitis B Virus-infected Women in 22 States, 2006. Pediatric Infectious Disease Journal 2011;30:575-9. [DOI: 10.1097/inf.0b013e31820cd65c] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
166 Lui YY, Chan HL. Treatment of chronic hepatitis B: focus on telbivudine. Expert Review of Anti-infective Therapy 2014;7:259-68. [DOI: 10.1586/eri.09.6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
167 Hui C, Cheung WW, Leung K, Cheng VCC, Tang BSF, Li IWS, Luk JM, Lee NP, Kwong Y, Au W, Yuen K, Lau GK, Liang R. Retracted : Outcome and immune reconstitution of HBV-specific immunity in patients with reactivation of occult HBV infection after alemtuzumab-containing chemotherapy regimen. Hepatology 2008;48:NA-NA. [DOI: 10.1002/hep.22213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
168 Férir G, Kaptein S, Neyts J, De Clercq E. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol. 2008;18:19-34. [PMID: 17966115 DOI: 10.1002/rmv.554] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
169 Cheruvu S, Marks K, Talal AH. Understanding the Pathogenesis and Management of Hepatitis B/HIV and Hepatitis B/Hepatitis C Virus Coinfection. Clinics in Liver Disease 2007;11:917-43. [DOI: 10.1016/j.cld.2007.08.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
170 Sheen E, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Nguyen MH. The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir: Entecavir for adefovir partial responders. Alimentary Pharmacology & Therapeutics 2011;34:767-74. [DOI: 10.1111/j.1365-2036.2011.04785.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
171 Assy N, Beniashvili Z, Djibre A, Nasser G, Grosovski M, Nseir W. Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg(-) chronic hepatitis B patients from inactive chronic carriers. World J Gastroenterol 2009; 15(24): 3025-3031 [PMID: 19554656 DOI: 10.3748/wjg.15.3025] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
172 Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474-1482. [PMID: 18008226 DOI: 10.1086/522608] [Cited by in Crossref: 129] [Cited by in F6Publishing: 126] [Article Influence: 8.6] [Reference Citation Analysis]
173 Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH. Hepatitis B virus infection and renal transplantation. World J Gastroenterol 2010; 16(31): 3878-3887 [PMID: 20712048 DOI: 10.3748/wjg.v16.i31.3878] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
174 Jain P. DNA-guided hepatitis B treatment: Viral load is insufficient with few exceptions. World J Gastroenterol 2009; 15(12): 1530-1531 [PMID: 19322931 DOI: 10.3748/wjg.15.1530] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
175 Croagh CMN, Bell SJ, Locarnini S, Desmond PV. Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing: HBV DNA in assessment of CHB. Internal Medicine Journal 2012;42:170-5. [DOI: 10.1111/j.1445-5994.2011.02435.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
176 Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075. [PMID: 17393513 DOI: 10.1002/hep.21627] [Cited by in Crossref: 407] [Cited by in F6Publishing: 371] [Article Influence: 27.1] [Reference Citation Analysis]
177 Yoo EH, Cho HJ. Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients. Clin Chim Acta 2017;471:308-13. [PMID: 28687350 DOI: 10.1016/j.cca.2017.06.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
178 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2013;57:6325-6332. [PMID: 24100506 DOI: 10.1128/aac.01742-13aac.01742-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Zhu X, Chen L, Fan W, Lin MC, Tian L, Wang M, Lin S, Wang Z, Zhang J, Wang J. An intronic variant in the GRP78, a stress-associated gene, improves prediction for liver cirrhosis in persistent HBV carriers. PLoS One. 2011;6:e21997. [PMID: 21779363 DOI: 10.1371/journal.pone.0021997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
180 Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, Lai ST, Wong WM, Lai LS, Poon RT, Lo CM, Fan ST, Lau GK; Hong Kong Liver Fibrosis Study Group. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology. 2007;46:690-698. [PMID: 17680649 DOI: 10.1002/hep.21758] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis]
181 Yun H, Kim T, Kim T, Choi HS, Bae S. Anti-TNF-α Therapy in Rheumatic Diseases with Chronic Hepatitis B Virus Infection. J Korean Rheum Assoc 2007;14:242. [DOI: 10.4078/jkra.2007.14.3.242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
182 Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55-68. [PMID: 19132805 DOI: 10.2165/00002018-200932010-00005] [Cited by in Crossref: 286] [Cited by in F6Publishing: 254] [Article Influence: 22.0] [Reference Citation Analysis]
183 Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2008;28:167-177. [PMID: 18466358 DOI: 10.1111/j.1365-2036.2008.03731.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
184 Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: A unique presentation of a common disease. J Gastroenterol Hepatol. 2009;24:1179-1186. [PMID: 19682192 DOI: 10.1111/j.1440-1746.2009.05924.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
185 Wang CC, Lim LY, Deubner H, Tapia K, Lau AW, Manansala J, Krows M, Shuhart MC, Kowdley KV. Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B and normal serum ALT. J Clin Gastroenterol. 2008;42:820-826. [PMID: 18458642 DOI: 10.1097/mcg.0b013e318156feef] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
186 Mangia A, Antonucci F, Brunetto M, Capobianchi M, Fagiuoli S, Guido M, Farci P, Lampertico P, Marzano A, Niro G. The use of molecular assays in the management of viral hepatitis. Dig Liver Dis. 2008;40:395-404. [PMID: 18321798 DOI: 10.1016/j.dld.2007.12.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
187 Gwak GY, Huh W, Lee DH, Choi MS, Lee JH, Koh KC, Kim SJ, Joh JW, Oh HY. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc. 2007;39:3121-3126. [PMID: 18089336 DOI: 10.1016/j.transproceed.2007.06.081] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
188 Chan HL, Wong GL, Choi PC, Chan AW, Chim AM, Yiu KK, Chan FK, Sung JJ, Wong VW. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16:36-44. [PMID: 18673426 DOI: 10.1111/j.1365-2893.2008.01037.x] [Cited by in Crossref: 293] [Cited by in F6Publishing: 291] [Article Influence: 20.9] [Reference Citation Analysis]
189 Park GH, Kim KY, Cho SW, Cheong JY, Yu GI, Shin DH, Kwack KB. Association between Interferon-Inducible Protein 6 (IFI6) Polymorphisms and Hepatitis B Virus Clearance. Genomics Inform 2013;11:15-23. [PMID: 23613678 DOI: 10.5808/GI.2013.11.1.15] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
190 Chan HL. Antiviral therapy for acute-on-chronic liver failure in chronic hepatitis B: is it too late? Dig Dis Sci 2010;55:2126-8. [PMID: 20458619 DOI: 10.1007/s10620-010-1266-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
191 Rao JG, Gao YF, Ye J, Wei YY, Li F, Zou GZ. Value of Forns index for noninvasive diagnosis of liver fibrosis in chronic hepatitis B patients. Shijie Huaren Xiaohua Zazhi 2015; 23(11): 1818-1824 [DOI: 10.11569/wcjd.v23.i11.1818] [Reference Citation Analysis]
192 Keshvari M, Alavian SM, Sharafi H. Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients. Jundishapur J Microbiol 2015;8:e21444. [PMID: 25973160 DOI: 10.5812/jjm.21444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
193 Kim BK, Kim DY, Park JY, Ahn SH, Chon CY, Kim JK, Paik YH, Lee KS, Park YN, Han KH. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30:546-553. [PMID: 20074094 DOI: 10.1111/j.1478-3231.2009.02192.x] [Cited by in Crossref: 144] [Cited by in F6Publishing: 142] [Article Influence: 12.0] [Reference Citation Analysis]
194 Thursz M, Cooke GS, Hall AJ. Hepatitis B treatment in resource poor settings: time for action. Trop Med Int Health. 2010;15:2-4. [PMID: 19843297 DOI: 10.1111/j.1365-3156.2009.02410.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
195 Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009;10:589-97. [PMID: 19482247 DOI: 10.1016/S1470-2045(09)70069-5] [Cited by in Crossref: 137] [Cited by in F6Publishing: 92] [Article Influence: 10.5] [Reference Citation Analysis]
196 Nagaoka S, Abiru S, Komori A, Sasaki R, Bekki S, Hashimoto S, Saeki A, Yamasaki K, Migita K, Nakamura M. Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long-term follow-up study. Hepatol Res. 2016;46:E89-E99. [PMID: 25951079 DOI: 10.1111/hepr.12533] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
197 Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis. Liver Int. 2016;36:1239-1251. [PMID: 27062182 DOI: 10.1111/liv.13142] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 10.8] [Reference Citation Analysis]
198 Mota LMHD, Cruz BA, Brenol CV, Pollak DF, Pinheiro GDRC, Laurindo IMM, Pereira IA, Carvalho JFD, Bertolo MB, Pinheiro MDM, Freitas MVC, Silva NAD, Louzada‐júnior P, Sampaio‐barros PD, Giorgi RDN, Lima RAC, Andrade LEC. Segurança do uso de terapias biológicas para o tratamento de artrite reumatoide e espondiloartrites. Revista Brasileira de Reumatologia 2015;55:281-309. [DOI: 10.1016/j.rbr.2014.06.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
199 Wiens A, Lenzi L, Venson R, Correr CJ, Rotta I, Pedroso ML, Pontarolo R. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2013;33:144-151. [PMID: 23359454 DOI: 10.1002/phar.1188] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
200 Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, Yeo W, Sung JJ, Mok TS. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177-182. [PMID: 18182659 DOI: 10.1200/jco.2007.13.2043] [Cited by in Crossref: 207] [Cited by in F6Publishing: 81] [Article Influence: 14.8] [Reference Citation Analysis]
201 Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G, Li LJ. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients. J Transl Med 2014;12:183. [PMID: 24962263 DOI: 10.1186/1479-5876-12-183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
202 Papatheodoridis GV. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues. Liver Int. 2011;31 Suppl 1:95-103. [PMID: 21205145 DOI: 10.1111/j.1478-3231.2010.02392.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
203 Nguyen NH, Trinh HN, Nguyen TT, Do ST, Tran P, Nguyen HA, Nguyen KK, Garcia RT, Lutchman GA, Nguyen MH. Safety and efficacy of entecavir in adefovir-experienced patients. J Gastroenterol Hepatol. 2015;30:43-50. [PMID: 25168842 DOI: 10.1111/jgh.12728] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
204 Oliveri F, Coco B, Ciccorossi P, Colombatto P, Romagnoli V, Cherubini B, Bonino F, Brunetto MR. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol. 2008;14:6154-6162. [PMID: 18985805 DOI: 10.3748/wig.14.6154] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
205 Das K, Sarkar R, Ahmed SM, Mridha AR, Mukherjee PS, Das K, Dhali GK, Santra A, Chowdhury A. "Normal" liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population-based study from a developing country. Hepatology 2012;55:584-93. [PMID: 21952989 DOI: 10.1002/hep.24694] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 5.5] [Reference Citation Analysis]
206 Yin J, Xie J, Zhang H, Shen Q, Han L, Lu W, Han Y, Li C, Ni W, Wang H, Cao G. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol 2010;45:1063-71. [DOI: 10.1007/s00535-010-0253-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
207 Sherman M. Prevention of hepatocellular carcinoma: the holy grail of hepatitis B treatment. J Hepatol. 2009;50:854-856. [PMID: 19303162 DOI: 10.1016/j.jhep.2009.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
208 Ahn SH, Park YK, Park ES, Kim JH, Kim DH, Lim KH, Jang MS, Choe WH, Ko SY, Sung IK. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88:6805-6818. [PMID: 24696492 DOI: 10.1128/jvi.00635-14] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
209 Afif W, Loftus EV. Safety Profile of IBD Therapeutics: Infectious Risks. Gastroenterology Clinics of North America 2009;38:691-709. [DOI: 10.1016/j.gtc.2009.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
210 Buster EH, Schalm SW, Janssen HL. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol. 2008;22:1093-1108. [PMID: 19187869 DOI: 10.1016/j.bpg.2008.11.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
211 Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, Mcnaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St.clair EW, Tindall E, Miller AS, Mcalindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis: ACR RA Treatment Recommendations. Arthritis Care & Research 2016;68:1-25. [DOI: 10.1002/acr.22783] [Cited by in Crossref: 601] [Cited by in F6Publishing: 482] [Article Influence: 85.9] [Reference Citation Analysis]
212 Yu JH, Lee JI. Current role of transient elastography in the management of chronic hepatitis B patients. Ultrasonography. 2017;36:86-94. [PMID: 27956732 DOI: 10.14366/usg.16023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
213 Alvarez-Uria G, Ratcliffe L, Vilar J. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort. HIV Med. 2009;10:269-273. [PMID: 19210695 DOI: 10.1111/j.1468-1293.2008.00683.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
214 Kuo YH, Chen CH, Wang JH, Hung CH, Tseng PL, Lu SN, Changchien CS, Lee CM. Extended lamivudine consolidation therapy in hepatitis B e antigen-positive chronic hepatitis B patients improves sustained hepatitis B e antigen seroconversion. Scand J Gastroenterol. 2010;45:75-81. [PMID: 20030580 DOI: 10.3109/00365520903394550] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
215 Ali K, Sial AA, Baig MT, Baig N, Ansari SH, Shamsi TS. Detection of the Incidence of HBV, HCV Infection and Febrile Neutropenia Associated With CHOP With or Without Rituximab in Diffuse Large B-Cell Lymphoma-Treated Patients. Hosp Pharm 2018;53:194-7. [PMID: 30147140 DOI: 10.1177/0018578717741394] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
216 Lenci I, Marcuccilli F, Tisone G, Di Paolo D, Tariciotti L, Ciotti M, Guenci T, Perno CF, Angelico M. Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis. Dig Liver Dis. 2010;42:578-584. [PMID: 20097143 DOI: 10.1016/j.dld.2009.12.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
217 Xu BY, Tan WT, Tan S, Dan YJ, Luo XL, Deng GH. Serum testosterone levels and androgen receptor CAG polymorphism correlate with hepatitis B virus (HBV)-related acute liver failure in male HBV carriers. PLoS One 2013;8:e84213. [PMID: 24391916 DOI: 10.1371/journal.pone.0084213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
218 Lee CI, Kwon SY, Kim JH, Choe WH, Lee CH, Yoon EL, Yeon JE, Byun KS, Kim YS, Kim JH. Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. Gut Liver. 2014;8:64-69. [PMID: 24516703 DOI: 10.5009/gnl.2014.8.1.64] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
219 Yokoyama Y, Fukunaga K, Kamikozuru K, Sato T, Kawai M, Nogami K, Nagase K, Nakamura M, Immured M, Hida N, Nakamura S. Crohn's disease complicated by hepatitis B virus successfully treated with the use of adsorptive depletion of myeloid lineage leucocytes to suppress inflammatory cytokine profile. Cytotherapy 2014;16:821-5. [PMID: 24713332 DOI: 10.1016/j.jcyt.2014.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
220 Yoo BC, Kim JH, Kim TH, Koh KC, Um SH, Kim YS, Lee KS, Han BH, Chon CY, Han JY, Ryu SH, Kim HC, Byun KS, Hwang SG, Kim BI, Cho M, Yoo K, Lee HJ, Hwang JS, Kim YS, Lee YS, Choi SK, Lee YJ, Yang JM, Park JW, Lee MS, Kim DG, Chung YH, Cho SH, Choi JY, Kweon YO, Lee HY, Jeong SH, Yoo HW, Lee HS. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007;46:1041-8. [PMID: 17647293 DOI: 10.1002/hep.21800] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 5.5] [Reference Citation Analysis]
221 Taylor VM, Bastani R, Burke N, Talbot J, Sos C, Liu Q, Carey Jackson J, Yasui Y. Factors associated with hepatitis B testing among Cambodian American men and women. J Immigr Minor Health. 2012;14:30-38. [PMID: 22002705 DOI: 10.1007/s10903-011-9536-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
222 Ginya H, Asahina J, Nakao R, Tamada Y, Takahashi M, Yohda M, Yatsuhashi H. Semi-quantitative discrimination of HBV mutants using allele-specific oligonucleotide hybridization with Handy Bio-Strand. J Biosci Bioeng 2010;109:94-100. [PMID: 20129090 DOI: 10.1016/j.jbiosc.2009.06.023] [Reference Citation Analysis]
223 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]
224 Milionis C. Serological markers of Hepatitis B and C among juvenile immigrants from Albania settled in Greece. Eur J Gen Pract. 2010;16:236-240. [PMID: 20954813 DOI: 10.3109/13814788.2010.525631] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
225 Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? Int J Infect Dis. 2011;15:e2-16. [PMID: 21074471 DOI: 10.1016/j.ijid.2010.03.025] [Cited by in Crossref: 131] [Cited by in F6Publishing: 108] [Article Influence: 10.9] [Reference Citation Analysis]
226 McDonald SA, van Lier A, Plass D, Kretzschmar ME. The impact of demographic change on the estimated future burden of infectious diseases: examples from hepatitis B and seasonal influenza in the Netherlands. BMC Public Health 2012;12:1046. [PMID: 23217094 DOI: 10.1186/1471-2458-12-1046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
227 He C, Gao PJ, Jing X, Wu Y. Factors affecting binding of beta 2-glycoprotein I to hepatitis B surface antigen in the serum of patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2011; 19(9): 887-891 [DOI: 10.11569/wcjd.v19.i9.887] [Reference Citation Analysis]
228 Domagalski K, Pawłowska M, Zaleśna A, Tyczyno M, Skorupa-Kłaput M, Tretyn A, Halota W. The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. Eur J Clin Microbiol Infect Dis 2014;33:2025-33. [PMID: 24924923 DOI: 10.1007/s10096-014-2172-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
229 Wang ZL, Gao S, Li XY, Sun FK, Li F, Fan YC, Wang K. Demethylation of tumor necrosis factor-α converting enzyme promoter associated with high hepatitis B e antigen level in chronic hepatitis B. World J Gastroenterol 2015; 21(27): 8382-8388 [PMID: 26217090 DOI: 10.3748/wjg.v21.i27.8382] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
230 Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, Negus SE, McMahon BJ. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133:1452-1457. [PMID: 17920063 DOI: 10.1053/j.gastro.2007.08.010] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 11.9] [Reference Citation Analysis]
231 Manesis EK. The natural history of chronic HBV infection. Curr hepatitis rep 2009;8:10-7. [DOI: 10.1007/s11901-009-0002-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
232 Peng H, Liu J, Yang M, Tong S, Yin W, Tang H, Hu P, Hu H, Ren H. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis. J Clin Pharmacol. 2014;54:189-200. [PMID: 24105676 DOI: 10.1002/jcph.181] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
233 van der Veen YJ, de Zwart O, Mackenbach J, Richardus JH. Cultural tailoring for the promotion of hepatitis B screening in Turkish Dutch: a protocol for a randomized controlled trial. BMC Public Health 2010;10:674. [PMID: 21054830 DOI: 10.1186/1471-2458-10-674] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
234 Etzion O, Ghany MG. Screening for hepatitis B virus to prevent viral reactivation - who and when? Clinical Liver Disease. 2015;5:47-50. [PMID: 31040948 DOI: 10.1002/cld.458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
235 Bright PD, Smith L, Usher J, Donati M, Johnston SL, Gompels MM, Unsworth DJ. False interpretation of diagnostic serology tests for patients treated with pooled human immunoglobulin G infusions: a trap for the unwary. Clin Med (Lond) 2015;15:125-9. [PMID: 25824062 DOI: 10.7861/clinmedicine.15-2-125] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
236 Caliendo AM, Valsamakis A, Bremer JW, Ferreira-Gonzalez A, Granger S, Sabatini L, Tsongalis GJ, Wang YF, Yen-Lieberman B, Young S, Lurain NS. Multilaboratory evaluation of real-time PCR tests for hepatitis B virus DNA quantification. J Clin Microbiol 2011;49:2854-8. [PMID: 21697326 DOI: 10.1128/JCM.00471-11] [Cited by in Crossref: 40] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
237 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol 2014; 20(24): 7635-7643 [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 8.1] [Reference Citation Analysis]
238 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immuno–suppressed patients. World J Hepatol. 2014;6:384-393. [PMID: 25018849 DOI: 10.4254/wjh.v6i6.384] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
239 Cai SH, Lv FF, Zhang YH, Jiang YG, Peng J. Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB. BMC Infect Dis. 2014;14:85. [PMID: 24528480 DOI: 10.1186/1471-2334-14-85] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
240 Wang Y, Xiao J, Ruan L, Zhang H, Chen M, Pu X, Shen H, Wu G. Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay. Clinica Chimica Acta 2009;408:70-4. [DOI: 10.1016/j.cca.2009.07.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
241 Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogiannakos J, Christias E, Saveriadis A, Pavlidis C, Triantos C, Christidou A, Papatheodoridis G, Karamanolis D, Tzourmakliotis D. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008;27:266-73. [PMID: 17988233 DOI: 10.1111/j.1365-2036.2007.03567.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
242 Cheng PN, Chang TT. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev Anti Infect Ther. 2008;6:569-579. [PMID: 18847396 DOI: 10.1586/14787210.6.5.569] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
243 Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl. 2008;14 Suppl 2:S8-S14. [PMID: 18825720 DOI: 10.1002/lt.21616] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
244 Barreiro P, Martín-Carbonero L, García-Samaniego J. [Hepatitis B in patients with HIV infection]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:71-9. [PMID: 19100234 DOI: 10.1016/s0213-005x(08)76522-4] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
245 Zheng Y, Zhang S, Tan Grahn HM, Ye C, Gong Z, Zhang Q. Prophylactic Lamivudine to Improve the Outcome of Breast Cancer Patients With HBsAg Positive During Chemotherapy: A Meta-Analysis. Hepat Mon. 2013;13:e6496. [PMID: 23805156 DOI: 10.5812/hepatmon.6496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
246 Visvanathan K, Lang T, Ryan K, Wilson R, Skinner NA, Thompson AJ, Ahn SH, Weilert F, Abbott W, Gane E, Colledge D, Li K, Locarnini S, Mansell A, Revill PA. Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients. J Viral Hepat 2016;23:170-9. [PMID: 26436722 DOI: 10.1111/jvh.12477] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
247 Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessoa MG, Fassio E, Ono SK, Bessone F, Daruich J. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One. 2013;8:e54279. [PMID: 23390496 DOI: 10.1371/journal.pone.0054279] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
248 Kim JH, Lee SJ, Joo MK, Kim CH, Choi JH, Jung YK, Yim HJ, Yeon JE, Park JJ, Kim JS. Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation. Dig Dis Sci. 2009;54:1572-1577. [PMID: 18975080 DOI: 10.1007/s10620-008-0508-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
249 Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013;37:544-555. [PMID: 23423795 DOI: 10.1002/jmri.23731] [Cited by in Crossref: 354] [Cited by in F6Publishing: 318] [Article Influence: 39.3] [Reference Citation Analysis]
250 Galmozzi E, Viganò M, Lampertico P. Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection? Aliment Pharmacol Ther. 2014;39:569-578. [PMID: 24461198 DOI: 10.1111/apt.12631] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
251 Wang Y, Liu S, Chen YU, Zheng S, Zhou LI, Lu F, Duan Z. Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. Exp Ther Med. 2016;11:2293-2299. [PMID: 27313669 DOI: 10.3892/etm.2016.3230] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
252 Cho WH, Lee HJ, Bang KB, Kim SB, Song IH. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature. World J Gastroenterol 2018; 24(17): 1919-1924 [PMID: 29740207 DOI: 10.3748/wjg.v24.i17.1919] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
253 Han Y, Tang Q, Zhu W, Zhang X, You L. Clinical, biochemical, immunological and virological profiles of, and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare. J Gastroenterol Hepatol. 2008;23:1728-1733. [PMID: 18823435 DOI: 10.1111/j.1440-1746.2008.05600.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
254 Zhong JH, Ke Y, Zhu SL, Wang L, Luo CP, Gong WF, You XM, Ma L, Xiang BD, Li LQ. Adefovir dipivoxil is less expensive than lamivudine and associated with similar prognosis in patients with hepatitis B virus-related hepatocellular carcinoma after radical resection. Onco Targets Ther 2016;9:6897-907. [PMID: 27877054 DOI: 10.2147/OTT.S120062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
255 Karamolahi S, Yazdi RS, Zangeneh M, Makiani MJ, Farhoodi B, Gilani MAS. Impact of hepatitis B virus and hepatitis C virus infection on sperm parameters of infertile men. Int J Reprod Biomed 2019;17:551-6. [PMID: 31583372 DOI: 10.18502/ijrm.v17i8.4820] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
256 Sellier P, Maylin S, Amarsy R, Mazeron MC, Larrouy L, Haïm-Boukobza S, Lopes A, Moreno MD, Ricbourg A, Simoneau G, Magnier JD, Mercier-Delarue S, Delcey V, Evans J, Cambau E, Barranger E, Simon F, Bergmann JF. Untreated highly viraemic pregnant women from Asia or sub-Saharan Africa often transmit hepatitis B virus despite serovaccination to newborns. Liver Int 2015;35:409-16. [PMID: 24698736 DOI: 10.1111/liv.12561] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
257 Kennedy PTF, Litwin S, Dolman GE, Bertoletti A, Mason WS. Immune Tolerant Chronic Hepatitis B: The Unrecognized Risks. Viruses 2017;9:E96. [PMID: 28468285 DOI: 10.3390/v9050096] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
258 Park YM, Jang JW, Yoo SH, Kim SH, Oh IM, Park SJ, Jang YS, Lee SJ. Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma. J Viral Hepat. 2014;21:171-177. [PMID: 24344773 DOI: 10.1111/jvh.12134] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
259 Andrade P, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. J Gastroenterol Hepatol. 2015;30:1591-1595. [PMID: 25967740 DOI: 10.1111/jgh.13001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
260 Lin YY, Huang JF, Liu SF, Yu ML, Tsai CH, Yang JF, Lin IL, Dai CY, Lin ZY, Chen SC, Chang WY, Chuang WL. Performance characteristics of two real-time PCR assays for quantification of hepatitis B virus DNA. Scand J Infect Dis 2009;41:614-8. [PMID: 19360504 DOI: 10.1080/00365540902875073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
261 Kim DY, Chang HY, Lim SM, Kim SU, Park JY, Kim JK, Lee KS, Han KH, Chon CY, Ahn SH. Quasispecies and pre-existing drug-resistant mutations of hepatitis B virus in patients with chronic hepatitis B. Gut Liver 2013;7:329-34. [PMID: 23710315 DOI: 10.5009/gnl.2013.7.3.329] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
262 Khelifa F, Thibault V. [Characteristics of hepatitis B viral strains in chronic carrier patients from North-East Algeria]. Pathol Biol (Paris) 2009;57:107-13. [PMID: 18835106 DOI: 10.1016/j.patbio.2008.07.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
263 Kwon JH, Park ST, Kim GD, You CR, Kim JD, Woo HY, Jang JW, Kim CW, Bae SH, Choi JY, Yoon SK. The value of serum retinol-binding protein 4 levels for determining disease severity in patients with chronic liver disease. Korean J Hepatol 2009;15:59. [DOI: 10.3350/kjhep.2009.15.1.59] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
264 Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018. Jpn J Clin Oncol 2020;50:1370-9. [PMID: 32719873 DOI: 10.1093/jjco/hyaa130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
265 Akima T, Tamano M, Yamagishi H, Kubota K, Fujimori T, Hiraishi H. Surgical treatment of HCC in a patient with lamivudine-resistant hepatitis B cirrhosis with adefovir dipivoxil. World J Hepatol 2010; 2(8): 318-321 [PMID: 21161015 DOI: 10.4254/wjh.v2.i8.318] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
266 Abdollahi M, Pouri A, Ghojazadeh M, Estakhri R, Somi M. Non-invasive serum fibrosis markers: A study in chronic hepatitis. Bioimpacts. 2015;5:17-23. [PMID: 25901293 DOI: 10.15171/bi.2015.05] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
267 Trinchet J. Carcinome hépatocellulaire : une incidence croissante, une prise en charge « optimisée ». Gastroentérologie Clinique et Biologique 2009;33:830-9. [DOI: 10.1016/j.gcb.2009.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
268 Nicolini LA, Zappulo E, Viscoli C, Mikulska M. Management of chronic viral hepatitis in the hematological patient. Expert Rev Anti Infect Ther 2018;16:227-41. [PMID: 29415584 DOI: 10.1080/14787210.2018.1438264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
269 Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States. Open Forum Infect Dis 2019;6:ofy353. [PMID: 30931346 DOI: 10.1093/ofid/ofy353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
270 Ramos CA, Saliba RM, de Pádua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:686-94. [PMID: 20056165 DOI: 10.1016/j.bbmt.2009.12.532] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
271 Gill US, Pallett LJ, Kennedy PTF, Maini MK. Liver sampling: A vital window into HBV pathogenesis on the path to functional cure. Gut. 2018;67:767-775. [PMID: 29331944 DOI: 10.1136/gutjnl-2017-314873] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
272 Taylor VM, Seng P, Acorda E, Sawn L, Li L. Hepatitis B knowledge and practices among Cambodian immigrants. J Cancer Educ 2009;24:100-4. [PMID: 19431024 DOI: 10.1080/08858190802664750] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
273 Zhang JY, Zou ZS, Huang A, Zhang Z, Fu JL, Xu XS, Chen LM, Li BS, Wang FS. Hyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. PLoS One. 2011;6:e17484. [PMID: 21390263 DOI: 10.1371/journal.pone.0017484] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 6.3] [Reference Citation Analysis]
274 Wang L, Liu F, Liu YD, Li XY, Wang JB, Zhang ZH, Wang YZ. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. J Viral Hepat. 2010;17:298-304. [PMID: 19758278 DOI: 10.1111/j.1365-2893.2009.01178.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
275 Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, Ohkawa K, Nadano S, Furuse J, Kudo M, Ito K, Yokoyama M, Okusaka T, Shimoyama M, Mizokami M. Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents. Hepatol Res 2015;45:1220-7. [PMID: 25627550 DOI: 10.1111/hepr.12496] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
276 Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Jiang Z, Liu J, Xu D. Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China. Hepatol Int. 2007;1:365-372. [PMID: 19669331 DOI: 10.1007/s12072-007-9009-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
277 Collins JM, Raphael KL, Terry C, Cartwright EJ, Pillai A, Anania FA, Farley MM. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis. 2015;61:1304-1306. [PMID: 26082511 DOI: 10.1093/cid/civ474] [Cited by in Crossref: 124] [Cited by in F6Publishing: 102] [Article Influence: 17.7] [Reference Citation Analysis]
278 Jang JS, Kim HS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, Kim DJ, Lee MS, Park CK. Association of concurrent hepatitis B surface antigen and antibody to hepatitis B surface antigen with hepatocellular carcinoma in chronic hepatitis B virus infection. J Med Virol. 2009;81:1531-1538. [PMID: 19623669 DOI: 10.1002/jmv.21577] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
279 Wei XL, Qiu MZ, Chen WW, Jin Y, Ren C, Wang F, Luo HY, Wang ZQ, Zhang DS, Wang FH, Li YH, Xu RH. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. J Transl Med 2013;11:249. [PMID: 24099678 DOI: 10.1186/1479-5876-11-249] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
280 Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, Guo Q, Gu R, Bao S. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010;48:22-6. [PMID: 20233672 DOI: 10.1016/j.jcv.2010.02.014] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 5.5] [Reference Citation Analysis]
281 Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. JCO 2009;27:605-11. [DOI: 10.1200/jco.2008.18.0182] [Cited by in Crossref: 458] [Cited by in F6Publishing: 175] [Article Influence: 35.2] [Reference Citation Analysis]
282 Lo Re V 3rd. Economic analysis of hepatitis B screening and treatment. Clin Infect Dis 2011;52:1307-9. [PMID: 21540207 DOI: 10.1093/cid/cir238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
283 Ratnam D, Visvanathan K. New concepts in the immunopathogenesis of chronic hepatitis B: the importance of the innate immune response. Hepatol Int. 2008;2:12-18. [PMID: 19669294 DOI: 10.1007/s12072-008-9067-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
284 Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Löhe F, Louhimo J, Sawczuk I, Taketa K, Diamandis EP; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48. [PMID: 20207771 DOI: 10.1373/clinchem.2009.133124] [Cited by in Crossref: 146] [Cited by in F6Publishing: 119] [Article Influence: 12.2] [Reference Citation Analysis]
285 Tong MJ, Nguyen MO, Tong LT, Blatt LM. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol. 2009;7:889-893. [PMID: 19394445 DOI: 10.1016/j.cgh.2009.04.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
286 Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S. Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis 2017;76:1051-6. [PMID: 27934678 DOI: 10.1136/annrheumdis-2016-209973] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
287 Ahn SH, Chan HL, Chen PJ, Cheng J, Goenka MK, Hou J, Lim SG, Omata M, Piratvisuth T, Xie Q, Yim HJ, Yuen MF; APPROACH Working Group. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int. 2010;4:386-395. [PMID: 20305758 DOI: 10.1007/s12072-010-9163-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
288 Song BC. Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? Clin Mol Hepatol 2016;22:439-42. [PMID: 28081595 DOI: 10.3350/cmh.2016.0108] [Reference Citation Analysis]
289 Buey LG, Mateos FG, Oteroa RM. Interferón en la hepatitis B. Enfermedades Infecciosas y Microbiología Clínica 2008;26:19-31. [DOI: 10.1016/s0213-005x(08)76516-9] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
290 Yun TJ, Jung JY, Kim CH, Um SH, An H, Seo YS, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS. Treatment strategies using adefovir dipivoxil for individuals with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2012; 18(47): 6987-6995 [PMID: 23322998 DOI: 10.3748/wjg.v18.i47.6987] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
291 Papatheodoridis GV, Manesis EK, Manolakopoulos S, Archimandritis AJ. Serum hepatitis B virus-DNA cutoff levels in hepatitis B e antigen–negative chronic hepatitis B virus infection. Hepatology 2007;46:606-7. [DOI: 10.1002/hep.21864] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
292 Su LN, Guo SL, Li BX, Yang P. Diagnostic value of magnetic resonance elastography for detecting and staging of hepatic fibrosis: a meta-analysis. Clin Radiol. 2014;69:e545-e552. [PMID: 25300557 DOI: 10.1016/j.crad.2014.09.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
293 Carvalhana SC, Leitão J, Alves AC, Bourbon M, Cortez-Pinto H. Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups. Eur J Gastroenterol Hepatol 2016;28:640-4. [PMID: 26866523 DOI: 10.1097/MEG.0000000000000608] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
294 Bronowicki JP, Nani A, Barraud H, Cadranel JF. [Is it possible to stop nucleos(t)ide analogue based therapy in chronic hepatitis B?]. Gastroenterol Clin Biol 2008;32:S50-5. [PMID: 18662610 DOI: 10.1016/S0399-8320(08)73265-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
295 Museru O, Franco-Paredes C. Epidemiology and clinical outcomes of hepatitis B virus infection among refugees seen at a U.S. travel medicine clinic: 2005-2008. Travel Med Infect Dis 2009;7:171-4. [PMID: 19411045 DOI: 10.1016/j.tmaid.2009.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
296 Shi B, Ren G, Hu Y, Wang S, Zhang Z, Yuan Z. HBsAg inhibits IFN-α production in plasmacytoid dendritic cells through TNF-α and IL-10 induction in monocytes. PLoS One 2012;7:e44900. [PMID: 23024774 DOI: 10.1371/journal.pone.0044900] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 5.8] [Reference Citation Analysis]
297 Mauss S, Wedemeyer H. Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Review of Anti-infective Therapy 2014;6:191-9. [DOI: 10.1586/14787210.6.2.191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
298 Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, McDonald B, Ong J, Stone J, Easterbrook P, Vickerman P. Prevalence and burden of HBV co-infection among people living with HIV: A global systematic review and meta-analysis. J Viral Hepat. 2020;27:294-315. [PMID: 31603999 DOI: 10.1111/jvh.13217] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
299 Amarapurkar DN, Patel N. Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection. Indian J Gastroenterol. 2014;33:89-91. [PMID: 23512213 DOI: 10.1007/s12664-013-0325-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
300 Micco L, Fiorino S, Loggi E, Lorenzini S, Vitale G, Cursaro C, Riili A, Bernardi M, Andreone P. Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report. BMJ Case Rep. 2009;2009:bcr06.2008.0287. [PMID: 21686872 DOI: 10.1136/bcr.06.2008.0287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
301 Tana MM, Ghany MG. Hepatitis B virus treatment: Management of antiviral drug resistance. Clin Liver Dis (Hoboken) 2013;2:24-8. [PMID: 30992816 DOI: 10.1002/cld.162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
302 Tanaka E, Matsumoto A, Yoshizawa K, Maki N. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy. Intervirology 2008;51 Suppl 1:3-6. [PMID: 18544941 DOI: 10.1159/000122592] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
303 Chang TT, Suh DJ. Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. Hepatol Int 2008;2:19-27. [PMID: 19669295 DOI: 10.1007/s12072-008-9059-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
304 Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, Kao WY, Chiu CF, Lin SF, Lin J, Chang CS, Tien HF, Liu TW, Chen PJ, Cheng AL;  Taiwan Cooperative Oncology Group. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092-2100. [PMID: 24002804 DOI: 10.1002/hep.26718] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 22.4] [Reference Citation Analysis]
305 Liao Y, Cai B, Li Y, Chen J, Tao C, Huang H, Wang L. Association of HLA-DP/DQ and STAT4 polymorphisms with HBV infection outcomes and a mini meta-analysis. PLoS One. 2014;9:e111677. [PMID: 25365208 DOI: 10.1371/journal.pone.0111677] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
306 Park SH, Kim CH, Kim DJ, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. Development and validation of a model to predict advanced fibrosis in chronic hepatitis B virus-infected patients with high viral load and normal or minimally raised ALT. Dig Dis Sci. 2011;56:1828-1834. [PMID: 21086167 DOI: 10.1007/s10620-010-1477-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
307 Wu S, Kanda T, Imazeki F, Arai M, Yonemitsu Y, Nakamoto S, Fujiwara K, Fukai K, Nomura F, Yokosuka O. Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines. Viral Immunol. 2010;23:467-476. [PMID: 20883161 DOI: 10.1089/vim.2010.0042] [Cited by in Crossref: 24] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
308 Tonziello G, Pisaturo M, Sica A, Ferrara MG, Sagnelli C, Pasquale G, Sagnelli E, Guastafierro S, Coppola N. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 2013;41:225-9. [DOI: 10.1007/s15010-012-0305-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
309 Han YT, Sun C, Liu CX, Xie SS, Xiao D, Liu L, Yu JH, Li WW, Li Q. Clinical features and outcome of acute hepatitis B in pregnancy. BMC Infect Dis. 2014;14:368. [PMID: 24993389 DOI: 10.1186/1471-2334-14-368] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
310 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
311 Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P; Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:909-20. [PMID: 21378402 DOI: 10.1136/ard.2010.144998] [Cited by in Crossref: 262] [Cited by in F6Publishing: 212] [Article Influence: 23.8] [Reference Citation Analysis]
312 Chen EQ, Dai J, Bai L, Tang H. The efficacy of zinc finger antiviral protein against hepatitis B virus transcription and replication in tansgenic mouse model. Virol J 2015;12:25. [PMID: 25889209 DOI: 10.1186/s12985-015-0245-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
313 Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2:147-151. [PMID: 19669299 DOI: 10.1007/s12072-008-9048-3] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 7.1] [Reference Citation Analysis]
314 Ha NB, Ha NB, Trinh HN, Nguyen HA, Nguyen KK, Nguyen MH. Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily. Journal of Clinical Gastroenterology 2013;47:461-5. [DOI: 10.1097/mcg.0b013e318266fd31] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
315 Rustgi V, Carriero D, Bachtold M, Zeldin G. Update on Chronic Hepatitis B. The Journal for Nurse Practitioners 2010;6:631-9. [DOI: 10.1016/j.nurpra.2010.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
316 Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91-98. [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
317 Wang YW, Shan X, Huang Y, Deng H, Huang WX, Zhang DZ, Chen J, Tang N, Shan YL, Guo JJ, Huang A. A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response. Infect Genet Evol 2015;33:269-76. [PMID: 25983054 DOI: 10.1016/j.meegid.2015.05.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
318 Hammond SP, Borchelt AM, Ukomadu C, Ho VT, Baden LR, Marty FM. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1049-1059. [PMID: 19660717 DOI: 10.1016/j.bbmt.2009.05.001] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 7.7] [Reference Citation Analysis]
319 Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ;  Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138:1747-1754. [PMID: 20114048 DOI: 10.1053/j.gastro.2010.01.042] [Cited by in Crossref: 213] [Cited by in F6Publishing: 192] [Article Influence: 17.8] [Reference Citation Analysis]
320 Liu L, Wang J, She W. Correlation between viral load and liver cirrhosis in chronic hepatitis B patients. Front Med China 2009;3:271-6. [DOI: 10.1007/s11684-009-0054-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
321 Tanaka E, Umemura T. History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. Clin J Gastroenterol 2008;1:83-6. [DOI: 10.1007/s12328-008-0030-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
322 Pratt DS. Hepatitis B: significant advances and unmet challenges: . Current Opinion in Gastroenterology 2009;25:173-4. [DOI: 10.1097/mog.0b013e32832a57e9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
323 Anbazhagan GK, Krishnamoorthy S, Thiyagarajan T. Seroprevalence of HCV and its co-infection with HBV and HIV among liver disease patients of South Tamil Nadu. World J Hepatol 2010; 2(1): 42-48 [PMID: 21160955 DOI: 10.4254/wjh.v2.i1.42] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
324 Shi M, Wei J, Dong J, Meng W, Ma J, Wang T, Wang N, Wang Y. Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis. Mol Med Rep. 2015;11:121-126. [PMID: 25323532 DOI: 10.3892/mmr.2014.2681] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
325 Hsu CW, Chao YC, Lee CM, Chang TT, Chen YC. Efficacy of telbivudine in Taiwanese chronic hepatitis B patients compared with GLOBE extension study and predicting treatment outcome by HBV DNA kinetics at week 24. BMC Gastroenterol 2012;12:178. [PMID: 23234302 DOI: 10.1186/1471-230X-12-178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
326 Li Y, He L, Li Y, Su M, Su J, Hou J, Deng J, Wang S, Wang Q, Xu X, Zhuang H, Li T. Characterization of Serum HBV RNA in Patients with Untreated HBeAg-Positive and -Negative Chronic Hepatitis B Infection. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
327 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
328 Matsumoto A, Tanaka E, Minami M, Okanoue T, Yatsuhashi H, Nagaoka S, Suzuki F, Kobayashi M, Chayama K, Imamura M, Yotsuyanagi H, Nakaoka S, Maki N, Kawata S, Kumada H, Iino S, Kiyosawa K. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatology Research 2007;37:661-6. [DOI: 10.1111/j.1872-034x.2007.00094.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
329 Papatheodoridis GV, Manolakopoulos S. EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J Hepatol. 2009;51:226-227. [PMID: 19410321 DOI: 10.1016/j.jhep.2009.02.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
330 Planas R, Morillas RM. Tratamiento de la infección por el virus de la hepatitis B. Estado actual y perspectivas. Gastroenterología y Hepatología 2008;31:349-55. [DOI: 10.1157/13123603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
331 Sagnelli E, Sagnelli C, Pisaturo M, Macera M, Coppola N. Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in Italy. World J Gastroenterol. 2014;20:7635-7643. [PMID: 24976701 DOI: 10.3748/wjg.v20.i24.7635.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
332 Nousbaum JB. [A 23-year-old asymptomatic HBsAg positive woman]. Gastroenterol Clin Biol 2009;33:F56-9. [PMID: 19762187 DOI: 10.1016/j.gcb.2009.07.029] [Reference Citation Analysis]
333 Vallet-Pichard A, Pol S. [Management of hepatitis B virus and hepatitis C virus infection in chronic kidney failure]. Nephrol Ther 2015;11:507-20. [PMID: 26423779 DOI: 10.1016/j.nephro.2015.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
334 Ohishi W, Chayama K. Current treatment for chronic hepatitis B in Japan. Clin J Gastroenterol 2009;2:325-30. [DOI: 10.1007/s12328-009-0100-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
335 Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol. 2012;31:1169-1175. [PMID: 22544263 DOI: 10.1007/s10067-012-1988-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
336 Warner BG, Abbott WG, Rodrigo AG. Frequency-dependent selection drives HBeAg seroconversion in chronic hepatitis B virus infection. Evol Med Public Health 2014;2014:1-9. [PMID: 24481244 DOI: 10.1093/emph/eot023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
337 Lai CL, Yuen MF. The saga of entecavir. Hepatol Int 2009;3:421-4. [PMID: 19669247 DOI: 10.1007/s12072-009-9138-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
338 Liaw YF. Towards a rational treatment strategy for chronic hepatitis B. Hepatol Int 2007;1:285-6. [PMID: 19669351 DOI: 10.1007/s12072-007-9005-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
339 Pan JS, Zhou F, Xie CX, Cai JY, Chen JM, Zhang ZP, Dong J, Xu HZ, Shi HX, Ren JL. Aldolase A-HBsAg interaction and its effect on ultraviolet radiation induced apoptosis in 293FT cells. J Gastroenterol Hepatol 2010;25:1702-9. [PMID: 20880182 DOI: 10.1111/j.1440-1746.2010.06237.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
340 Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, Yokosuka O. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication. Scand J Gastroenterol 2011;46:1111-7. [PMID: 21623676 DOI: 10.3109/00365521.2011.584898] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
341 Jinjuvadia R, Liangpunsakul S, Antaki F. Past exposure to hepatitis B: a risk factor for increase in mortality? J Clin Gastroenterol. 2014;48:267-271. [PMID: 23751854 DOI: 10.1097/mcg.0b013e3182972254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
342 Dan YY, Aung MO, Lim SG. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2008;2:284-95. [PMID: 19669256 DOI: 10.1007/s12072-008-9049-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
343 Al-Busafi SA, Hilzenrat N. Mild Hypertransaminasemia in Primary Care. ISRN Hepatol. 2013;2013:256426. [PMID: 27335825 DOI: 10.1155/2013/256426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
344 Wang H, Xue L, Yan R, Zhou Y, Wang MS, Cheng MJ, Huang HJ. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 2013;20:e3-10. [PMID: 23490387 DOI: 10.1111/jvh.12010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
345 Tan W, Xia J, Dan Y, Li M, Lin S, Pan X, Wang H, Tang Y, Liu N, Tan S, Liu M, He W, Zhang W, Mao Q, Wang Y, Deng G. Genome-wide association study identifies HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure. Gut 2018;67:757-66. [PMID: 28130311 DOI: 10.1136/gutjnl-2016-313035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
346 Wang J, Zhang P, Liao J, Zhu Y, Liu X, Tang H. Association of α-fetoprotein levels with liver stiffness measurement in outpatients with chronic hepatitis B. Biosci Rep 2021;41:BSR20203048. [PMID: 33289529 DOI: 10.1042/BSR20203048] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Tosun S, Yücetürk M, Dönmez AB, Gündüz T. Rapid immunization scheme for spouses of individuals estabilished as hepatitis B carriers during premarital tests. Clin Dev Immunol 2012;2012:843134. [PMID: 23304191 DOI: 10.1155/2012/843134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
348 Fassio E, Díaz S, Santa C, Elisa Reig M, Martínez Artola Y, Alves de Mattos A, Míguez C, Galizzi J, Zapata R, Ridruejo E, Carlos de Souza F, Hernández N, Pinchuk L. Etiology of hepatocellular carcinoma in Latin America: a prospective, multicenter, international study. Annals of Hepatology 2010;9:63-9. [DOI: 10.1016/s1665-2681(19)31681-3] [Cited by in Crossref: 31] [Article Influence: 2.6] [Reference Citation Analysis]
349 Larrubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol. 2011;17:1529-1530. [PMID: 21472115 DOI: 10.3748/wjg.v17.i12] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
350 Li M, Zhou ZH, Sun XH, Zhang X, Zhu XJ, Jin SG, Jiang Y, Gao YT, Li CZ, Gao YQ. The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection. Hepatol Int 2016;10:594-601. [PMID: 26924524 DOI: 10.1007/s12072-015-9650-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
351 Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients. J Gastroenterol Hepatol. 2010;25:892-898. [PMID: 20546442 DOI: 10.1111/j.1440-1746.2009.06161.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
352 Ma SW, Li YY, Zhang GW, Huang X, Sun J, Li C, Abbott WG, Hou JL. Complementarity-determining region 3 size spectratypes of T cell receptor beta chains in CD8+ T cells following antiviral treatment of chronic hepatitis B. Antimicrob Agents Chemother 2011;55:888-94. [PMID: 21098256 DOI: 10.1128/AAC.01232-10] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
353 Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009;3:425-33. [PMID: 19669245 DOI: 10.1007/s12072-009-9140-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 6.1] [Reference Citation Analysis]
354 Taylor VM, Hislop TG, Tu SP, Teh C, Acorda E, Yip MP, Woodall E, Yasui Y. Evaluation of a hepatitis B lay health worker intervention for Chinese Americans and Canadians. J Community Health 2009;34:165-72. [PMID: 19127416 DOI: 10.1007/s10900-008-9138-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
355 Sestili C, Grazina I, La Torre G. HBV vaccine and risk of developing multiple sclerosis: a systematic review and meta-analysis. Hum Vaccin Immunother 2021;17:2273-8. [PMID: 30260264 DOI: 10.1080/21645515.2018.1528835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
356 Liu D, Ni B, Wang L, Zhang M, Liu W, Wu Y. Hepatitis B virus core protein interacts with CD59 to promote complement-mediated liver inflammation during chronic hepatitis B virus infection. FEBS Lett 2013;587:3314-20. [PMID: 24036449 DOI: 10.1016/j.febslet.2013.08.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
357 Liu Y, Zhang Y, Yuan J, Zeng W, Zhang G, Yao S, Li H, Yang M, Deng Y, Zou R. Efficacy of tenofovir disoproxil fumarate therapy in Chinese chronic hepatitis B patients after multiple antiviral failures. Hepatol Res. 2015;45:E43-E52. [PMID: 25429855 DOI: 10.1111/hepr.12454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
358 Reijnders JG, Janssen HL. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol. 2008;48:383-386. [PMID: 18191272 DOI: 10.1016/j.jhep.2007.12.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
359 Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol 2021;116:1885-95. [PMID: 33927125 DOI: 10.14309/ajg.0000000000001271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Zhang N, Reijnders JGP, Perquin M, Hansen BE, Janssen HLA. Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. Journal of Viral Hepatitis 2011;18. [DOI: 10.1111/j.1365-2893.2011.01448.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
361 Cho SW, Cho YJ, Cheong JY, Lee MH, Jeon SJ, Lee YC, Lim SG, Kang CJ. [Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients]. Korean J Gastroenterol 2010;56:83-9. [PMID: 20729619 DOI: 10.4166/kjg.2010.56.2.83] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
362 Lee HW, Park JY, Ahn SH. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. Expert Rev Gastroenterol Hepatol 2016;10:177-86. [PMID: 26610256 DOI: 10.1586/17474124.2016.1125781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
363 Peng H, Wei F, Liu J, Hu H, Ren H, Hu P. Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis. Hepatol Int 2015;9:543-57. [DOI: 10.1007/s12072-015-9644-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
364 Ghany MG, Feld JJ, Zhao X, Heller T, Doo E, Rotman Y, Nagabhyru P, Koh C, Kleiner DE, Wright EC, Liang TJ, Hoofnagle JH. Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. Aliment Pharmacol Ther 2012;35:1027-35. [PMID: 22449251 DOI: 10.1111/j.1365-2036.2012.05059.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 0.2] [Reference Citation Analysis]
365 Martin CM, Welge JA, Rouster SD, Shata MT, Sherman KE, Blackard JT. Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro. J Viral Hepat. 2012;19:716-723. [PMID: 22967103 DOI: 10.1111/j.1365-2893.2012.01595.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
366 Stevens K, Palmo T, Wangchuk T, Solomon S, Dierberg K, Hoffmann CJ. Hepatitis B prevalence and treatment needs among Tibetan refugees residing in India. J Med Virol 2016;88:1357-63. [PMID: 26822932 DOI: 10.1002/jmv.24488] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
367 Moriconi F, Colombatto P, Coco B, Ciccorossi P, Oliveri F, Flichman D, Maina AM, Sacco R, Bonino F, Brunetto MR. Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment. J Antimicrob Chemother. 2007;60:341-349. [PMID: 17567633 DOI: 10.1093/jac/dkm187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
368 Wu XJ, Wang Y, Chen J, Wang GQ. Baseline predictors of virological response for chronic hepatitis B patients. World J Gastroenterol 2009; 15(34): 4311-4315 [PMID: 19750575 DOI: 10.3748/wjg.15.4311] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
369 Zhang F, Wang G. A review of non-nucleoside anti-hepatitis B virus agents. Eur J Med Chem 2014;75:267-81. [PMID: 24549242 DOI: 10.1016/j.ejmech.2014.01.046] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
370 Ambang T, Tan JS, Ong S, Wong KT, Goh KJ. Clinicopathological Features of Telbivudine-Associated Myopathy. PLoS One 2016;11:e0162760. [PMID: 27611456 DOI: 10.1371/journal.pone.0162760] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
371 Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009;101:1066-1082. [PMID: 19574418 DOI: 10.1093/jnci/djp180.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
372 Gong X, Zhu Y, Dong J, Chen J, You J, Zheng Q, Rao Z, Mao Q, Jiang J. Small hepatitis B surface antigen interacts with and modulates enoyl-coenzyme A hydratase expression in hepatoma cells. Arch Virol 2013;158:1065-70. [PMID: 23275097 DOI: 10.1007/s00705-012-1581-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
373 Jeon SR, Jang JY, Jeong SW, Park SH, Lee SH, Kim SG, Cheon YK, Kim YS, Cho YD, Moon JH, Kim HS, Lee JS, Kim BS. HBV DNA loss within 24 weeks predicts late viral breakthrough in chronic hepatitis B. Korean J Gastroenterol 2011;58:25-30. [PMID: 21778800 DOI: 10.4166/kjg.2011.58.1.25] [Reference Citation Analysis]
374 Wen S, Wu Y, Pan Y, Cao M, Zhao D, Wang C, Wang C, Kong F, Li J, Niu J, Jiang J. Association of IL-10 and IL-10RA single nucleotide polymorphisms with the responsiveness to HBV vaccination in Chinese infants of HBsAg(+)/HBeAg(-) mothers: a nested case-control study. BMJ Open 2018;8:e022334. [PMID: 30498038 DOI: 10.1136/bmjopen-2018-022334] [Reference Citation Analysis]
375 Li M, Zhou ZH, Sun XH, Zhang X, Zhu XJ, Jin SG, Gao YT, Jiang Y, Gao YQ. Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence. Lab Invest 2016;96:1156-64. [PMID: 27617403 DOI: 10.1038/labinvest.2016.96] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
376 Cassinotto C, Lapuyade B, Aït-Ali A, Vergniol J, Gaye D, Foucher J, Bailacq-Auder C, Chermak F, Le Bail B, de Lédinghen V. Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. Radiology. 2013;269:283-292. [PMID: 23630312 DOI: 10.1148/radiol.13122208] [Cited by in Crossref: 80] [Cited by in F6Publishing: 78] [Article Influence: 8.9] [Reference Citation Analysis]
377 Lei B, Liu Y, Dong C, Chen X, Zhang X, Diao X, Yang G, Liu J, Yao S, Li H, Yuan J, Li S, Le X, Lin Y, Zeng W. Assessment of liver fibrosis in chronic hepatitis B via multimodal data. Neurocomputing 2017;253:169-76. [DOI: 10.1016/j.neucom.2016.09.128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
378 Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology. 2009;49:1859-1867. [PMID: 19378345 DOI: 10.1002/hep.22878] [Cited by in Crossref: 111] [Cited by in F6Publishing: 100] [Article Influence: 8.5] [Reference Citation Analysis]
379 Cho Y, Song B. New Insight for HBV DNA and HBsAg Quantitation during Antiviral Therapy in Patients with Chronic Hepatitis B. Korean J Gastroenterol 2011;57:144. [DOI: 10.4166/kjg.2011.57.3.144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
380 Weisberg IS, Brown RS, Sigal SH. Hepatitis B and End-Stage Liver Disease. Clinics in Liver Disease 2007;11:893-916. [DOI: 10.1016/j.cld.2007.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
381 Shen X, Fu B, Liu Y, Guo C, Ye Y, Sun R, Li J, Tian Z, Wei H. NKp30+ NK cells are associated with HBV control during pegylated-interferon-alpha-2b therapy of chronic hepatitis B. Sci Rep 2016;6:38778. [PMID: 27941937 DOI: 10.1038/srep38778] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
382 Chen Y, Ju T. Comparative meta-analysis of adefovir dipivoxil monotherapy and combination therapy of adefovir dipivoxil and lamivudine for lamivudine-resistant chronic hepatitis B. Int J Infect Dis 2012;16:e152-8. [PMID: 22226087 DOI: 10.1016/j.ijid.2011.11.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
383 Yeo SJ, Lee HS, Jang BI, Kim ES, Jeon SW, Kim SK, Kim KO, Lee YJ, Lee HJ, Park KS, Jung YJ, Kim EY, Yang CH; Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD). Nonimmunity against hepatitis B virus infection in patients newly diagnosed with inflammatory bowel disease. Intest Res 2018;16:400-8. [PMID: 30090039 DOI: 10.5217/ir.2018.16.3.400] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
384 Pan CQ, Trinh H, Yao A, Bae H, Lou L, Chan S; Study 123 Group. Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings. PLoS One 2014;9:e89789. [PMID: 24594870 DOI: 10.1371/journal.pone.0089789] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
385 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
386 Gao S, Fan Y, Zhao J, Sun F, Han J, Zhao Z, Wang K. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase ≤2 upper limit of normal. Liver Int 2014;34:e229-37. [DOI: 10.1111/liv.12344] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
387 Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47:447-454. [PMID: 18080339 DOI: 10.1002/hep.22075] [Cited by in Crossref: 129] [Cited by in F6Publishing: 127] [Article Influence: 9.2] [Reference Citation Analysis]
388 Degertekin B, Lok AS. Do guidelines preclude hepatitis B patients from receiving treatment? Hepatology 2009;49:700-1. [DOI: 10.1002/hep.22722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
389 Zhuang G, Zhang M, Liu Y, Guo Y, Wu Q, Zhou K, Ji Z, Zhang X. Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls. Health Qual Life Outcomes. 2014;12:101. [PMID: 24928466 DOI: 10.1186/1477-7525-12-101] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
390 Pei SN, Ma MC, Wang MC, Kuo CY, Rau KM, Su CY, Chen CH. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol. 2012;91:1007-1012. [PMID: 22273839 DOI: 10.1007/s00277-012-1405-6] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 6.2] [Reference Citation Analysis]
391 Gisbert JP, Chaparro M. Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol 2013;10:277-85. [PMID: 23419290 DOI: 10.1038/nrgastro.2013.28] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
392 Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond). 2018;18:212-218. [PMID: 29858430 DOI: 10.7861/clinmedicine.18-3-212] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
393 Pan HY, Pan HY, Chen L, Yang DH, Huang HJ, Tong YX, Chen CR, Yan J. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients. Clin Microbiol Infect 2015;21:1123.e1-9. [PMID: 26253290 DOI: 10.1016/j.cmi.2015.07.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
394 Li J, Shi TD, Han JF, Zeng XG, Fan CL, Han C, Liu HL, Wu YZ. A systematic study of Tupaia as a model for human acute hepatitis B infection. J Vet Med Sci 2021;83:1004-11. [PMID: 33952781 DOI: 10.1292/jvms.21-0026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Wu X, Li X, Chen Z, Wen J, Lin Q, Xing Y, Dong M, Wei L, Wang T, Chen J, Lin Z, Wan X, Ruan D, Ma X. An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study. Tumor Biol 2013;34:909-18. [DOI: 10.1007/s13277-012-0626-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
396 Matei HV, Vica ML, Siserman CV. Association between HLA class II alleles and hepatitis B virus infection in Transylvania, Romania. Immunol Invest 2018;47:735-44. [PMID: 29979894 DOI: 10.1080/08820139.2018.1489832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
397 Tada T, Kumada T, Toyoda H, Ito T, Sone Y, Okuda S, Tsuji N, Imayoshi Y, Yasuda E. Utility of real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C infection without cirrhosis: Comparison of liver fibrosis indices: Liver fibrosis evaluated using SWE in CHC. Hepatol Res 2015;45:E122-9. [DOI: 10.1111/hepr.12476] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
398 Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:619-633. [PMID: 21416659 DOI: 10.1111/j.1365-2036.2010.04570.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
399 Kim BG, Jung SW, Kim EH, Kim JH, Park JH, Sung SJ, Park BR, Kim M, Kim CJ, Lee BU, Park JH, Jeong ID, Bang S, Shin JW, Park NH. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir: Tenofovir in multidrug resistant hepatitis B. J Gastroenterol Hepatol 2015;30:1514-21. [DOI: 10.1111/jgh.12993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
400 Zhao Y, Kang H, Peng JH, Xu L, Cao ZW, Hu YY. Key symptoms selection for two major syndromes diagnosis of Chinese medicine in chronic hepatitis B. Chin J Integr Med. 2017;23:253-260. [PMID: 27225292 DOI: 10.1007/s11655-016-2253-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
401 Karabay O, Tuna N, Yahyaoglu M. Hepatitis B viral breakthrough associated with inappropriate preservation of entecavir. Indian J Pharmacol 2012;44:136-7. [PMID: 22345891 DOI: 10.4103/0253-7613.91889] [Reference Citation Analysis]
402 Li G, Xie F, Yan S, Hu X, Jin B, Wang J, Wu J, Yin D, Xie Q. Subhealth: definition, criteria for diagnosis and potential prevalence in the central region of China. BMC Public Health 2013;13:446. [PMID: 23642312 DOI: 10.1186/1471-2458-13-446] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
403 Gutiérrez A, Viciana I, Rius F, Pinedo A. [Mutations in precore/basal core promoter regions and viral polymerase in patients with chronic hepatitis B]. Enferm Infecc Microbiol Clin 2012;30:70-4. [PMID: 22112677 DOI: 10.1016/j.eimc.2011.08.008] [Reference Citation Analysis]
404 Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Miailhes P, Lassel L, Delaugerre C, Girard PM, Zoulim F, Lacombe K. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. AIDS 2012;26:939-49. [PMID: 22333748 DOI: 10.1097/QAD.0b013e328352224d] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
405 Potter M, Klein MB. Co-infections and co-therapies: treatment of HIV in the presence of hepatitis C and hepatitis B. HIV Therapy 2009;3:189-207. [DOI: 10.2217/17584310.3.2.189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
406 Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, Kim TY, Sohn JH, Lee HS. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol. 2010;37:346-350. [PMID: 20008922 DOI: 10.3899/jrheum.090436] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
407 Chien R, Liaw Y. Current treatment of chronic HBV infection: An Asian-Pacific perspective. Curr hepatitis rep 2009;8:154-60. [DOI: 10.1007/s11901-009-0022-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
408 Du Y, Su T, Ding Y, Cao G. Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation. Hepat Mon. 2012;12:e6031. [PMID: 23166535 DOI: 10.5812/hepatmon.6031] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
409 Haider M, Flocco G, Lopez R, Carey W. Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab. BMJ Open 2020;10:e043672. [PMID: 33323450 DOI: 10.1136/bmjopen-2020-043672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
410 Zobeiri M. Occult hepatitis B: clinical viewpoint and management. Hepat Res Treat. 2013;2013:259148. [PMID: 23533738 DOI: 10.1155/2013/259148] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
411 But DY, Yuen MF, Fung J, Lai CL. Safety evaluation of telbivudine. Expert Opin Drug Saf. 2010;9:821-829. [PMID: 20662545 DOI: 10.1517/14740338.2010.507190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
412 Dimzova M, Kondova-Topuzovska I, Bosilkovski M, Ivanovski L, Milenkovic Z, Semenakova-Cvetkovska V, Orovcanec N. Noninvasive Biomarkers in Assessment of Liver Fibrosis in Patients with HBeAg Negative Chronic Hepatitis B. Open Access Maced J Med Sci 2018;6:1052-8. [PMID: 29983800 DOI: 10.3889/oamjms.2018.122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
413 Watanabe M, Shibuya A, Tsunoda Y, Danbara M, Ishii R, Ohsaka M, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Horie R, Higashihara M, Koizumi W. Re-appearance of hepatitis B virus following therapy with rituximab for lymphoma is not rare in Japanese patients with past hepatitis B virus infection: Re-appearance of HBV after chemotherapy. Liver International 2011;31:340-7. [DOI: 10.1111/j.1478-3231.2010.02417.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
414 Fung J, Lai C, But D, Wong D, Cheung T, Yuen M. Prevalence of Fibrosis and Cirrhosis in Chronic Hepatitis B: Implications for Treatment and Management. Am J Gastroenterology 2008;103:1421-6. [DOI: 10.1111/j.1572-0241.2007.01751.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
415 Requena T, Martín MT, Desongles T, Castillo I, Lorente L, Yébenes M; and the EUPTHEA Group. Prescription pattern for antivirals in the treatment of chronic hepatitis B: the EUPTHEA Study. Eur J Hosp Pharm 2013;20:174-9. [DOI: 10.1136/ejhpharm-2012-000206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
416 Brunetto MR. Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance. Journal of Hepatology 2007;46:756-8. [DOI: 10.1016/j.jhep.2007.02.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
417 Hui C, Leung N, Yuen S, Zhang H, Leung K, Lu L, Cheung SKF, Wong W, Lau GK; Hong Kong Liver Fibrosis Study Group. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007;46:395-401. [DOI: 10.1002/hep.21724] [Cited by in Crossref: 142] [Cited by in F6Publishing: 146] [Article Influence: 9.5] [Reference Citation Analysis]
418 Yang YF, Zhao W, Zhong YD, Yang YJ, Shen L, Zhang N, Huang P. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res 2008;77:136-41. [PMID: 18078676 DOI: 10.1016/j.antiviral.2007.10.014] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
419 Zou CJ, Zhu LJ, Li YH, Mo YQ, Zheng DH, Ma JD, Ou-Yang X, Pessler F, Dai L. The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. Clin Rheumatol. 2013;32:787-795. [PMID: 23340833 DOI: 10.1007/s10067-013-2170-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
420 Cavallone D, Moriconi F, Colombatto P, Oliveri F, Bonino F, Brunetto MR. Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line. Journal of Virological Methods 2013;189:110-7. [DOI: 10.1016/j.jviromet.2013.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
421 Lau GKK. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon. Liver International 2009;29:125-9. [DOI: 10.1111/j.1478-3231.2008.01946.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
422 Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141-1150. [PMID: 19338056 DOI: 10.1002/hep.22760] [Cited by in Crossref: 336] [Cited by in F6Publishing: 308] [Article Influence: 25.8] [Reference Citation Analysis]
423 Nierhoff J, Chávez Ortiz AA, Herrmann E, Zeuzem S, Friedrich-rust M. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. Eur Radiol 2013;23:3040-53. [DOI: 10.1007/s00330-013-2927-6] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 13.3] [Reference Citation Analysis]
424 Ito H, Kanbe A, Hara A, Ishikawa T. Induction of humoral and cellular immune response to HBV vaccine can be up-regulated by STING ligand. Virology. 2019;531:233-239. [PMID: 30928701 DOI: 10.1016/j.virol.2019.03.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
425 Mammas IN, Greenough A, Theodoridou M, Kramvis A, Christaki I, Koutsaftiki C, Koutsaki M, Portaliou DM, Kostagianni G, Panagopoulou P, Sourvinos G, Spandidos DA. Current views and advances on Paediatric Virology: An update for paediatric trainees. Exp Ther Med 2016;11:6-14. [PMID: 26889211 DOI: 10.3892/etm.2015.2890] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
426 Li Z, Lei Z, Xia Y, Li J, Wang K, Zhang H, Wan X, Yang T, Zhou W, Wu M, Pawlik TM, Lau WY, Shen F. Association of Preoperative Antiviral Treatment With Incidences of Microvascular Invasion and Early Tumor Recurrence in Hepatitis B Virus-Related Hepatocellular Carcinoma. JAMA Surg 2018;153:e182721. [PMID: 30073257 DOI: 10.1001/jamasurg.2018.2721] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
427 Gluud LL, Gluud C. Meta-analyses on viral hepatitis. Infect Dis Clin North Am 2009;23:315-30. [PMID: 19393912 DOI: 10.1016/j.idc.2009.01.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
428 Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol. 2011;26 Suppl 1:131-137. [PMID: 21199524 DOI: 10.1111/j.1440-1746.2010.06544.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
429 Zhang R, Real CI, Liu C, Baba HA, Gerken G, Lu M, Broering R. Hepatic expression of oncogenes Bmi1 and Dkk1 is up-regulated in hepatitis B virus surface antigen-transgenic mice and can be induced by treatment with HBV particles or lipopolysaccharides in vitro. Int J Cancer 2017;141:354-63. [PMID: 28419472 DOI: 10.1002/ijc.30742] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
430 Karino Y, Toyota J, Kumada H, Katano Y, Izumi N, Kobashi H, Sata M, Moriyama M, Imazeki F, Kage M. Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int. 2010;4:414-422. [PMID: 20305760 DOI: 10.1007/s12072-009-9162-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
431 Yin J, Ji Z, Liang P, Wu Q, Cui F, Wang F, Liang X, Zhuang G. The doses of 10 μg should replace the doses of 5 μg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. Vaccine 2015;33:3731-8. [PMID: 26057138 DOI: 10.1016/j.vaccine.2015.05.082] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
432 Mengiste DA, Dirbsa AT, Ayele BH, Hailegiyorgis TT. Hepatitis B virus infection and its associated factors among medical waste collectors at public health facilities in eastern Ethiopia: a facility-based cross-sectional study. BMC Infect Dis 2021;21:233. [PMID: 33639871 DOI: 10.1186/s12879-021-05918-x] [Reference Citation Analysis]
433 Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: Systematic review and meta-analysis. J Viral Hepat. 2008;15:89-102. [PMID: 18184191 DOI: 10.1111/j.1365-2893.2007.00902.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 40] [Article Influence: 0.6] [Reference Citation Analysis]
434 Asselah T, Lada O, Moucari R, Martinot M, Boyer N, Marcellin P. Interferon Therapy for Chronic Hepatitis B. Clinics in Liver Disease 2007;11:839-49. [DOI: 10.1016/j.cld.2007.08.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
435 Kim TW, Kim MN, Kwon JW, Kim KM, Kim SH, Kim W, Park HW, Chang YS, Cho SH, Min KU. Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids. Respirology. 2010;15:1092-1097. [PMID: 20630033 DOI: 10.1111/j.1440-1843.2010.01798.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
436 Heo NY, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir. J Hepatol. 2010;53:449-454. [PMID: 20646776 DOI: 10.1016/j.jhep.2010.03.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
437 Montineri A, Nigro L, Chiarenza A, Larocca L, La Rosa R, Iacobello C, Di Raimondo F, Fatuzzo F. Telbivudine use in a patient affected by occult hepatitis B virus and B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 2010;51:554-7. [DOI: 10.3109/10428190903553961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
438 Pawłowska M, Halota W, Smukalska E, Woźniakowska-Gęsicka T, Kupś J. HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B. Eur J Clin Microbiol Infect Dis 2012;31:571-4. [PMID: 21796345 DOI: 10.1007/s10096-011-1349-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
439 Ruggeri M, Cicchetti A, Gasbarrini A. The cost-effectiveness of alternative strategies against HBV in Italy. Health Policy 2011;102:72-80. [DOI: 10.1016/j.healthpol.2010.09.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
440 Walter SR, Thein H, Amin J, Gidding HF, Ward K, Law MG, George J, Dore GJ. Trends in mortality after diagnosis of hepatitis B or C infection: 1992–2006. Journal of Hepatology 2011;54:879-86. [DOI: 10.1016/j.jhep.2010.08.035] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
441 Ying SY, Hu YR, Gao GS, Lou KH, Huang Z. Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis. Front Med (Lausanne) 2021;8:691365. [PMID: 34307418 DOI: 10.3389/fmed.2021.691365] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Anderson AM, Lennox JL. Antiretroviral therapy: when to start and which drugs to use. Curr Infect Dis Rep 2008;10:332-9. [PMID: 18765108 DOI: 10.1007/s11908-008-0053-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
443 Liu WC, Lin CP, Cheng CP, Ho CH, Lan KL, Cheng JH, Yen CJ, Cheng PN, Wu IC, Li IC, Chang BC, Tseng VS, Chiu YC, Chang TT. Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virus. Hepatol Int 2016;10:147-57. [PMID: 26208819 DOI: 10.1007/s12072-015-9645-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
444 Lok AS. Should antiviral treatment be extended to patients with chronic hepatitis B and mildly elevated alanine aminotransferase? Hepatology 2010;51:1107-9. [DOI: 10.1002/hep.23496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
445 Karra VK, Gumma PK, Chowdhury SJ, Ruttala R, Polipalli SK, Chakravarti A, Kar P. IL-18 polymorphisms in hepatitis B virus related liver disease. Cytokine. 2015;73:277-282. [PMID: 25802197 DOI: 10.1016/j.cyto.2015.02.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
446 Shen Y, Zhang J, Cai H, Shao JG, Zhang YY, Liu YM, Qin G, Qin Y. Identifying patients with chronic hepatitis B at high risk of type 2 diabetes mellitus: a cross-sectional study with pair-matched controls. BMC Gastroenterol. 2015;15:32. [PMID: 25887997 DOI: 10.1186/s12876-015-0263-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
447 Yan L, Zhu X, Bai L, Liang L, Chen E, Du L, Wang L, Chen L, Tang H. Impact of mild to moderate elevations of alanine aminotransferase on liver stiffness measurement in chronic hepatitis B patients during antiviral therapy: ALT and fibroscan. Hepatology Research 2013;43:185-91. [DOI: 10.1111/j.1872-034x.2012.01068.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.9] [Reference Citation Analysis]
448 Liang DY, Sha S, Yi Q, Shi J, Chen Y, Hou Y, Chang Q. Hepatitis B X protein upregulates decoy receptor 3 expression via the PI3K/NF-κB pathway. Cell Signal 2019;62:109346. [PMID: 31229617 DOI: 10.1016/j.cellsig.2019.109346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
449 Coban S, Kekilli M, Köklü S. Approach and management of patients with chronic hepatitis B and C during the course of inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2142-50. [PMID: 25072501 DOI: 10.1097/MIB.0000000000000126] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
450 Nash KL, Alexander GJ. The case for combination antiviral therapy for chronic hepatitis B virus infection. Lancet Infect Dis 2008;8:444-8. [PMID: 18485825 DOI: 10.1016/S1473-3099(08)70102-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
451 Jang JY, Park EJ. [Occult hepatitis B virus infection in chronic hepatitis C]. Korean J Gastroenterol 2013;62:154-9. [PMID: 24077625 DOI: 10.4166/kjg.2013.62.3.154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
452 Wang K, Yang H, He W, Xia Y, Xia Z, Li S, Huang H, Li Z, Liu P, Jiang W. Association between extranodal natural killer/T-cell lymphoma and hepatitis B viral infection: a case-control study. J Cancer 2017;8:2676-83. [PMID: 28928855 DOI: 10.7150/jca.19665] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
453 Degertekin B, Lok AS. Update on viral hepatitis: 2007. Curr Opin Gastroenterol. 2008;24:306-311. [PMID: 18408458 DOI: 10.1097/mog.0b013e3282f70285] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
454 Montineri A, Nigro L, La Rosa R, Iacobello C, Larocca L, Cappello E, Fiumara PF, Di Raimondo F, Fatuzzo F. Treatment induced seroconversion to HBsAb following HBV reactivation in the immunosuppressed haematology and oncology patient: a clinical survey of 5 cases in Catania, Italy. J Clin Virol 2011;52:284-7. [PMID: 21906994 DOI: 10.1016/j.jcv.2011.08.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
455 Elbedewy TA, Elashtokhy HE, Rabee ES, Kheder GE. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening. J Egypt Natl Canc Inst. 2015;27:11-18. [PMID: 25716703 DOI: 10.1016/j.jnci.2015.01.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
456 Wang Q, Luan W, Warren L, Fiel MI, Blank S, Kadri H, Tuvin D, Hiotis SP. Serum hepatitis B surface antigen correlates with tissue covalently closed circular DNA in patients with hepatitis B-associated hepatocellular carcinoma: HBsAg in HBV-HCC. J Med Virol 2016;88:244-51. [DOI: 10.1002/jmv.24326] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
457 Charatcharoenwitthaya P, Kaewdech A, Piratvisuth T. Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa. Clin Liver Dis 2021;25:741-62. [PMID: 34593151 DOI: 10.1016/j.cld.2021.06.004] [Reference Citation Analysis]
458 Hadziyannis SJ. Unrevealing the natural course of the so-called “inactive HBsAg or HBV carrier state”. Hepatol Int. 2007;1:281-284. [PMID: 19669350 DOI: 10.1007/s12072-007-9004-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
459 Lim SG. Telbivudine: a hepatitis B-specific antiviral. Expert Rev Clin Pharmacol 2008;1:217-29. [PMID: 24422647 DOI: 10.1586/17512433.1.2.217] [Reference Citation Analysis]
460 Xu WP, Wang ZR, Zou X, Zhao C, Wang R, Shi PM, Yuan ZL, Yang F, Zeng X, Wang PQ, Sultan S, Zhang Y, Xie WF. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein evaluates liver function and predicts prognosis in liver cirrhosis. J Dig Dis. 2018;19:242-253. [PMID: 29607614 DOI: 10.1111/1751-2980.12596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
461 Gisbert JP, Menchén L, García-Sánchez V, Marín I, Villagrasa JR, Chaparro M. Comparison of the effectiveness of two protocols for vaccination (standard and double dosage) against hepatitis B virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:1379-1385. [PMID: 22530631 DOI: 10.1111/j.1365-2036.2012.05110.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 5.6] [Reference Citation Analysis]
462 Li X, Xing Y, Lin Q, Dong M, Wan X, Wu X. The treatment of severe hepatitis B virus reactivation after chemotherapy. Nat Rev Clin Oncol 2012;9:350-350. [DOI: 10.1038/nrclinonc.2012.1-c1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
463 Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, Chan HY, Chan FK, Sung JJ, Chan HL. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol. 2009;7:227-233. [PMID: 19121647 DOI: 10.1016/j.cgh.2008.10.023] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
464 Zhang JC, Nie QH. New antiviral choice for chronic hepatitis B: tenofovir disoproxil fumarate. Shijie Huaren Xiaohua Zazhi 2008; 16(24): 2679-2688 [DOI: 10.11569/wcjd.v16.i24.2679] [Reference Citation Analysis]
465 Guy J, Yee HF Jr. Health disparities in liver disease: Time to take notice and take action. Hepatology 2009;50:309-13. [PMID: 19554619 DOI: 10.1002/hep.22942] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
466 Huang YW, Hu CY, Chen CL, Liao YT, Liu CJ, Lai MY, Chen PJ, Yang SS, Hu JT, Chen DS. Human leukocyte antigen-DRB1*1101 correlates with less severe hepatitis in Taiwanese male carriers of hepatitis B virus. J Med Virol. 2009;81:588-593. [PMID: 19235869 DOI: 10.1002/jmv.21448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
467 Lai MW, Lin TY, Tsao KC, Huang CG, Hsiao MJ, Liang KH, Yeh CT. Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology. 2012;143:400-407. [PMID: 22580098 DOI: 10.1053/j.gastro.2012.05.002] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
468 Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, Lee WM, Dixon S, Woessner M, Brosgart CL, Condreay LD, Gardner SD. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int 2011;5:654-63. [PMID: 21484148 DOI: 10.1007/s12072-010-9228-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
469 Yin J, Xie J, Zhang H, Shen Q, Han L, Lu W, Han Y, Li C, Ni W, Wang H. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol. 2010;45:1063-1071. [PMID: 20419326 DOI: 10.1007/s00535-010-0253-1.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
470 Lin MT, Yen YH, Tsai MC, Tseng PL, Chang KC, Wu CK, Hu TH. Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice. PLoS One 2016;11:e0165416. [PMID: 27806120 DOI: 10.1371/journal.pone.0165416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
471 Cheong JY, Cho SW, Oh B, Kimm K, Lee KM, Shin SJ, Lee JA, Park BL, Cheong HS, Shin HD. Association of interleukin-18 gene polymorphisms with hepatitis B virus clearance. Dig Dis Sci. 2010;55:1113-1119. [PMID: 19466545 DOI: 10.1007/s10620-009-0819-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
472 Panda B, Panda A, Riley LE. Selected Viral Infections in Pregnancy. Obstetrics and Gynecology Clinics of North America 2010;37:321-31. [DOI: 10.1016/j.ogc.2010.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
473 Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1323-1331. [PMID: 21050234 DOI: 10.1111/j.1365-2036.2010.04474.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 81] [Article Influence: 6.9] [Reference Citation Analysis]
474 Sansone S, Guarino M, Castiglione F, Rispo A, Auriemma F, Loperto I, Rea M, Caporaso N, Morisco F. Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3516-3524 [PMID: 24707134 DOI: 10.3748/wjg.v20.i13.3516] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
475 Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: Comparison of current treatment guidelines. World J Gastroenterol 2012; 18(42): 6106-6113 [PMID: 23155339 DOI: 10.3748/wjg.v18.i42.6106] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
476 Koumbi L. Current and future antiviral drug therapies of hepatitis B chronic infection. World J Hepatol 2015; 7(8): 1030-1040 [PMID: 26052392 DOI: 10.4254/wjh.v7.i8.1030] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
477 King LY, Chung RT. When treating cancer, please don't forget hepatitis B. Oncologist 2010;15:826-9. [PMID: 20647389 DOI: 10.1634/theoncologist.2009-0282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
478 Osborn M. Hepatitis B in HIV: available treatment options and approach to therapy. Curr Infect Dis Rep 2009;11:407-13. [PMID: 19698285 DOI: 10.1007/s11908-009-0057-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
479 Jin YJ, Shim JH, Chung YH, Kim JA, Choi JG, Park WH, Lee D, Kim SE, Lee YS, Kim SH, Yang SH. HLA-DRB1*010101 allele is closely associated with poor virological response to lamivudine therapy in patients with chronic hepatitis B. Digestion 2011;84 Suppl 1:35-42. [PMID: 22156484 DOI: 10.1159/000333783] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
480 Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23:512-520. [PMID: 18397482 DOI: 10.1111/j.1440-1746.2008.05384.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 117] [Article Influence: 9.6] [Reference Citation Analysis]
481 Walters J, Sullivan A. Early Identification and Linkage to Care of Foreign-Born People with Chronic Hepatitis B Virus Infection, Multnomah County, Oregon, 2012-2014. Public Health Rep 2016;131 Suppl 2:105-11. [PMID: 27168669 DOI: 10.1177/00333549161310S216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
482 Peters MG. Special populations with hepatitis B virus infection. Hepatology. 2009;49:S146-S155. [PMID: 19399810 DOI: 10.1002/hep.22965] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
483 Rodríguez M, González-Diéguez ML. [Clinical management of patients with chronic hepatitis B virus infection]. Enferm Infecc Microbiol Clin 2008;26 Suppl 7:56-65. [PMID: 19100232 DOI: 10.1016/s0213-005x(08)76520-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
484 Luo K, Mao Q, Karayiannis P, Liu D, Liu Z, Zhou Y, Feng X, Zhu Y, Guo Y, Jiang R, Zhou F, Peng J, Hou J. Tailored regimen of interferon alpha for HBeAg-positive chronic hepatitis B: a prospective controlled study. Journal of Viral Hepatitis 2008;15:684-9. [DOI: 10.1111/j.1365-2893.2008.00995.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
485 Yoon KT, Lim SM, Park JY, Kim do Y, Ahn SH, Han KH, Chon CY, Cho M, Lee JW, Kim SU. Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci. 2012;57:1682-1691. [PMID: 22302243 DOI: 10.1007/s10620-012-2044-4] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 6.8] [Reference Citation Analysis]
486 Zeng T, Xu H, Liu JY, Lei Y, Zhong S, Zhou Z. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis. J Clin Pharmacol 2014;54:959-67. [PMID: 24964070 DOI: 10.1002/jcph.351] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
487 Moses SE, Lim Z, Zuckerman MA. Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther. 2011;9:891-899. [PMID: 21973301 DOI: 10.1586/eri.11.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
488 Dusheiko G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 2013;33 Suppl 1:137-150. [PMID: 23286858 DOI: 10.1111/liv.12078] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
489 Bottecchia M, Garcia-Samaniego J, Soriano V. The implications of antiviral drugs with activity against hepatitis B virus and HIV. Curr Opin Infect Dis 2007;20:621-8. [PMID: 17975413 DOI: 10.1097/QCO.0b013e3282f1e022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
490 Kim DW, Lee SA, Kim H, Won YS, Kim BJ. Naturally occurring mutations in the nonstructural region 5B of hepatitis C virus (HCV) from treatment-naïve Korean patients chronically infected with HCV genotype 1b. PLoS One. 2014;9:e87773. [PMID: 24489961 DOI: 10.1371/journal.pone.0087773] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
491 Sagnelli C, Macera M, Pisaturo M, Zampino R, Coppola M, Sagnelli E. Occult HBV infection in the oncohematological setting. Infection. 2016;44:575-582. [PMID: 27076347 DOI: 10.1007/s15010-016-0891-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
492 Tang W, Chen L, Zheng R, Pan L, Gao J, Ye X, Zhang X, Zheng W. Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis. PLoS One 2015;10:e0128673. [PMID: 26057738 DOI: 10.1371/journal.pone.0128673] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
493 Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55-68. [PMID: 19132805 DOI: 10.2165/00002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
494 Zhang Q, Yin J, Zhang Y, Deng Y, Ji X, Du Y, Pu R, Han Y, Zhao J, Han X. HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations. J Virol. 2013;87:12176-12186. [PMID: 24006435 DOI: 10.1128/jvi.02073-13] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
495 Su CW, Wu CY, Hung HH, Wu CH, Sheen IJ, Wu JC. Differential roles of serum hepatitis B virus DNA and hepatitis B surface antigen level in predicting virological breakthrough in patients receiving lamivudine therapy. J Gastroenterol Hepatol. 2013;28:1849-1858. [PMID: 23730852 DOI: 10.1111/jgh.12283] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
496 Reardon JM, O'Connor SM, Njau JD, Lam EK, Staton CA, Cookson ST. Cost-effectiveness of birth-dose hepatitis B vaccination among refugee populations in the African region: a series of case studies. Confl Health 2019;13:5. [PMID: 30858875 DOI: 10.1186/s13031-019-0188-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
497 Berg T, Benhamou Y, Calleja JL, Levrero M, Johnson W, Ellis N. A survey of chronic hepatitis B patient management practices in the European Union. J Viral Hepat. 2010;17:624-630. [PMID: 20487257 DOI: 10.1111/j.1365-2893.2010.01318.x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
498 Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52:1251-1257. [PMID: 20830787 DOI: 10.1002/hep.23844] [Cited by in Crossref: 207] [Cited by in F6Publishing: 190] [Article Influence: 17.3] [Reference Citation Analysis]
499 Arnold DM, Crowther MA, Meyer RM, Carruthers J, Ditomasso J, Heddle NM, McLeod A, Kelton JG. Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia. Transfusion 2010;50:2577-81. [PMID: 20576011 DOI: 10.1111/j.1537-2995.2010.02766.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
500 Jindal A, Kumar M, Sarin SK. Management of acute hepatitis B and reactivation of hepatitis B. Liver Int 2013;33:164-75. [DOI: 10.1111/liv.12081] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
501 Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, Zou Y, Xu Q, An G, Li G. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One. 2013;8:e68568. [PMID: 23844222 DOI: 10.1371/journal.pone.0068568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
502 Zarski JP, Leroy V. [The patient with uncontrolled chronic hepatitis B]. Gastroenterol Clin Biol 2008;32:S7-11. [PMID: 18662613 DOI: 10.1016/S0399-8320(08)73259-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
503 Wu S, Kanda T, Imazeki F, Nakamoto S, Shirasawa H, Yokosuka O. Nuclear receptor mRNA expression by HBV in human hepatoblastoma cell lines. Cancer Lett. 2011;312:33-42. [PMID: 21903321 DOI: 10.1016/j.canlet.2011.07.025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
504 Nie H, Evans AA, London WT, Block TM, Ren XD. Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach. J Clin Microbiol 2011;49:2440-8. [PMID: 21562108 DOI: 10.1128/JCM.02472-10] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
505 Lee D, Chung Y, Lee SH, Kim SE, Lee Y, Kim KM, Lim YS, Lee HC, Lee YS, Yu E. Effect of Response to Interferon-a Therapy on the Occurrence of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Dig Dis 2012;30:568-73. [DOI: 10.1159/000343068] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
506 Watanabe M, Shibuya A, Takada J, Tanaka Y, Okuwaki Y, Minamino T, Hidaka H, Nakazawa T, Koizumi W. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Eur J Intern Med. 2010;21:333-337. [PMID: 20603047 DOI: 10.1016/j.ejim.2010.04.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
507 Ruiz-sancho A, Sheldon J, Soriano V. Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opinion on Biological Therapy 2007;7:751-61. [DOI: 10.1517/14712598.7.5.751] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
508 Les I, García-martínez R, Córdoba J, Quintana M, Esteban R, Buti M. Current trends in chronic hepatitis B management: results of a questionnaire. European Journal of Gastroenterology & Hepatology 2009;21:1177-83. [DOI: 10.1097/meg.0b013e3283154f3a] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
509 Yang SH, Hsu C, Cheng AL, Kuo SH. Anti-CD20 monoclonal antibodies and associated viral hepatitis in hematological diseases. World J Hematol 2014; 3(2): 29-43 [DOI: 10.5315/wjh.v3.i2.29] [Reference Citation Analysis]
510 Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2009;18:1655-1666. [PMID: 19852566 DOI: 10.1517/13543780903241599] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
511 Segovia MC, Chacra W, Gordon SC. Adefovir dipivoxil in chronic hepatitis B: history and current uses. Expert Opin Pharmacother 2012;13:245-54. [PMID: 22242973 DOI: 10.1517/14656566.2012.649727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
512 Manolakopoulos S, Striki A, Deutsch M, Mela M, Ketikoglou I, Tzourmakliotis D, Manesis EK, Papatheodoridis GV. Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver Int. 2011;31:1525-1532. [PMID: 22093327 DOI: 10.1111/j.1478-3231.2011.02616.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
513 Charbel H, Lewis JH. Hepatitis B Reactivation in the Setting of Chemotherapy and Immunosuppression. In: Shetty K, Wu GY, editors. Chronic Viral Hepatitis. Totowa: Humana Press; 2010. pp. 307-36. [DOI: 10.1007/978-1-59745-565-7_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
514 Fang J, Wichroski MJ, Levine SM, Baldick CJ, Mazzucco CE, Walsh AW, Kienzle BK, Rose RE, Pokornowski KA, Colonno RJ, Tenney DJ. Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates. Antimicrob Agents Chemother 2009;53:2762-72. [PMID: 19433559 DOI: 10.1128/AAC.00130-09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
515 Maklad S, Reyad EM, William EA, Abouzeid A. Efficacy and Safety of Entecavir 0. 5 mg in Treating Naive Chronic Hepatitis B Virus Patients in Egypt: Five Years of Real Life Experience. Gastroenterology Res 2018;11:138-44. [PMID: 29707081 DOI: 10.14740/gr965w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
516 Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N. Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 2014; 6(6): 384-393 [PMID: 25018849 DOI: 10.4254/wjh.v6.i6.384] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
517 Huang R, Jiang N, Yang R, Geng X, Lin J, Xu G, Liu D, Chen J, Zhou G, Wang S, Luo T, Wu J, Liu X, Xu K, Yang X. Fibroscan improves the diagnosis sensitivity of liver fibrosis in patients with chronic hepatitis B. Exp Ther Med. 2016;11:1673-1677. [PMID: 27168788 DOI: 10.3892/etm.2016.3135] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
518 Bohne F, Protzer U. Adoptive T-cell therapy as a therapeutic option for chronic hepatitis B. J Viral Hepat 2007;14 Suppl 1:45-50. [PMID: 17958642 DOI: 10.1111/j.1365-2893.2007.00913.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
519 Liu YP, Yang XN, Jazag A, Pan JS, Hu TH, Liu JJ, Guleng B, Ren JL. HBsAg inhibits the translocation of JTB into mitochondria in HepG2 cells and potentially plays a role in HCC progression. PLoS One. 2012;7:e36914. [PMID: 22615844 DOI: 10.1371/journal.pone.0036914] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
520 Zoutendijk R, Sonneveld MJ, Reijnders JG, van Vuuren AJ, Biesta P, Hansen BE, Boonstra A, Janssen HL. Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues. J Viral Hepat 2013;20:322-7. [PMID: 23565614 DOI: 10.1111/jvh.12033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
521 Enomoto M, Tamori A, Kohmoto MT, Hayashi T, Morikawa H, Jomura H, Sakaguchi H, Habu D, Kawada N, Shiomi S. Optimal duration of additional therapy after biochemical and virological responses to lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomized trial. Hepatol Res. 2008;38:954-959. [PMID: 18498358 DOI: 10.1111/j.1872-034x.2008.00378.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
522 Eskandari E, Metanat M, Pahlevani E, Nakhzari-Khodakheir T. Association between TGFβ1 polymorphisms and chronic hepatitis B infection in an Iranian population. Rev Soc Bras Med Trop 2017;50:301-8. [PMID: 28700046 DOI: 10.1590/0037-8682-0266-2016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
523 Chung GE, Kim W, Lee KL, Hwang SY, Lee JH, Kim HY, Jung YJ, Kim D, Jeong JB, Kim BG. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B. Dig Dis Sci. 2011;56:2130-2136. [PMID: 21253834 DOI: 10.1007/s10620-010-1561-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
524 Li X, Lin Q, Dong M, Wen J, Wei L, Ma X, Chen Z, Wu X. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leukemia & Lymphoma 2010;51:1678-85. [DOI: 10.3109/10428194.2010.499486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
525 Pawlotsky JM. [Virologic techniques for the diagnosis and monitoring of hepatitis B]. Gastroenterol Clin Biol. 2008;32:S56-S63. [PMID: 18662611 DOI: 10.1016/s0399-8320(08)73266-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
526 Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial. The Lancet Gastroenterology & Hepatology 2017;2:877-89. [DOI: 10.1016/s2468-1253(17)30288-1] [Cited by in Crossref: 100] [Cited by in F6Publishing: 43] [Article Influence: 20.0] [Reference Citation Analysis]
527 Crane M, Matthews G, Lewin SR. Hepatitis virus immune restoration disease of the liver. Curr Opin HIV AIDS 2008;3:446-52. [PMID: 19373004 DOI: 10.1097/COH.0b013e3282fdc953] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
528 Kim BK, Kim SU, Kim HS, Park JY, Ahn SH, Chon CY, Cho IR, Joh DH, Park YN, Han KH, Kim DY. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012;7:e35825. [PMID: 22536445 DOI: 10.1371/journal.pone.0035825] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
529 Yun J, Kim KH, Kang ES, Gwak GY, Choi MS, Lee JE, Nam SJ, Yang JH, Park YH, Ahn JS, Im YH. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011;104:559-563. [PMID: 21285992 DOI: 10.1038/bjc.2011.4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
530 Zhao XY, Zeng X, Li XM, Wang TL, Wang BE. Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. Clin Exp Pharmacol Physiol 2009;36:963-8. [PMID: 19413596 DOI: 10.1111/j.1440-1681.2009.05194.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
531 Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev. 2008;22:117-126. [PMID: 18343002 DOI: 10.1016/j.blre.2008.02.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
532 Carrera E, Manzano R, Garrido E. Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol 2013; 19(9): 1349-1353 [PMID: 23538553 DOI: 10.3748/wjg.v19.i9.1349] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
533 Eun Y, Kim IY, Jeong H, Kim H, Lee J, Choi MS, Koh E, Cha HS. Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. J Korean Med Sci 2018;33:e168. [PMID: 29853822 DOI: 10.3346/jkms.2018.33.e168] [Reference Citation Analysis]
534 Vallet-Pichard A, Pol S. Hepatitis B virus treatment beyond the guidelines: special populations and consideration of treatment withdrawal. Therap Adv Gastroenterol. 2014;7:148-155. [PMID: 25057295 DOI: 10.1177/1756283x14524614] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
535 You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li YL, Lei H, Liu J, Chen HY, Tang BZ. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis. 2008;8:123. [PMID: 18803883 DOI: 10.1186/1471-2334-8-123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
536 Lin B, Ha NB, Liu A, Trinh HN, Nguyen HA, Nguyen KK, Ahmed A, Keeffe EB, Garcia RT, Garcia G. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013;28:855-860. [PMID: 23278507 DOI: 10.1111/jgh.12108] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
537 Andreani T. HBV-carriers: When is monitoring and surveillance sufficient? (point of view). Clin Res Hepatol Gastroenterol 2011;35:813-8. [PMID: 21821479 DOI: 10.1016/j.clinre.2011.06.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
538 Liao Y, Hu X, Chen J, Cai B, Tang J, Ying B, Wang H, Wang L. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One. 2012;7:e38394. [PMID: 22675557 DOI: 10.1371/journal.pone.0038394] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
539 Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90. [PMID: 18049472 DOI: 10.1038/nrd2422] [Cited by in Crossref: 746] [Cited by in F6Publishing: 725] [Article Influence: 49.7] [Reference Citation Analysis]
540 Fan HB, Guo YB, Zhu YF, Chen AS, Zhou MX, Li Z, Xu LT, Ma XJ, Yan FM. Hepatitis B Virus Genotype B and High Expression of Interferon Alpha Receptor β Subunit are Associated With Better Response to Pegylated Interferon Alpha 2a in Chinese Patients With Chronic Hepatitis B Infection. Hepat Mon. 2012;12:333-338. [PMID: 22783345 DOI: 10.5812/hepatmon.6173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
541 Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Saito S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol. 2012;47:1022-1029. [PMID: 22370817 DOI: 10.1007/s00535-012-0561-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
542 Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2:263-283. [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
543 Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960-974. [PMID: 18395077 DOI: 10.1053/j.gastro.2008.01.034] [Cited by in Crossref: 963] [Cited by in F6Publishing: 885] [Article Influence: 68.8] [Reference Citation Analysis]
544 Wang C, Fan R, Sun J, Hou J. Prevention and management of drug resistant hepatitis B virus infections: Facing antiviral drug resistance. Journal of Gastroenterology and Hepatology 2012;27:1432-40. [DOI: 10.1111/j.1440-1746.2012.07198.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
545 Fontana RJ. Hepatitis B: A “GLOBAL” Health Challenge. Gastroenterology 2009;136:389-92. [DOI: 10.1053/j.gastro.2008.12.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
546 Liu MH, Sheng YJ, Liu JY, Hu HD, Zhang QF, Ren H. Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis. Ann Saudi Med 2013;33:169-76. [PMID: 23563007 DOI: 10.5144/0256-4947.2013.169] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
547 Taramasso L, Caligiuri P, Di Biagio A, Bruzzone B, Rosso R, Icardi G, Viscoli C. Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B. J Med Virol 2011;83:1905-8. [PMID: 21915864 DOI: 10.1002/jmv.22192] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
548 Chan HL, Wong VW. Hepatitis B. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 540-63. [DOI: 10.1016/b978-1-4377-0881-3.00030-9] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
549 Chen Y, Huang Z, Ma D, Chen L, Lai Q, Huang X, Zhou J, Zhang X, Ma Q, Chen Z, Zuo D. Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B. BMC Immunol 2015;16:29. [PMID: 25982058 DOI: 10.1186/s12865-015-0088-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
550 Hui CK, Lau GK. Treatment of Hepatitis B e Antigen-negative Patients. Curr Treat Options Gastroenterol 2007;10:474-82. [PMID: 18221608 DOI: 10.1007/s11938-007-0047-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
551 Chen M, Jagya N, Bansal R, Frelin L, Sällberg M. Prospects and progress of DNA vaccines for treating hepatitis B. Expert Rev Vaccines. 2016;15:629-640. [PMID: 26652035 DOI: 10.1586/14760584.2016.1131615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
552 Wang D, Chen TW, Zhang XM, Li J, Zeng NL, Li L, Tang YL, Huang YC, Li R, Chen F, Chen YL. Liver Lobe Based Multi-Echo Gradient Recalled Echo T2*-Weighted Imaging in Chronic Hepatitis B-Related Cirrhosis: Association with the Presence and Child-Pugh Class of Cirrhosis. PLoS One 2016;11:e0154545. [PMID: 27171422 DOI: 10.1371/journal.pone.0154545] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
553 Visram A, Chan KK, McGee P, Boro J, Hicks LK, Feld JJ. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening. PLoS One. 2015;10:e0120749. [PMID: 25875198 DOI: 10.1371/journal.pone.0120749] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
554 Foster GR. Recent advances in viral hepatitis. Clin Med (Lond) 2009;9:613-6. [PMID: 20095313 DOI: 10.7861/clinmedicine.9-6-613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
555 Yoon JH, Shin S, In Jw, Chang JY, Song EY, Roh EY. Association of HLA alleles with the responsiveness to hepatitis B virus vaccination in Korean infants. Vaccine. 2014;32:5638-5644. [PMID: 25148772 DOI: 10.1016/j.vaccine.2014.08.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
556 Chang TT. On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. Hepatol Int 2009;3 Suppl 1:16-23. [PMID: 19669242 DOI: 10.1007/s12072-009-9143-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
557 Gallego A, Sheldon J, García-Samaniego J, Margall N, Romero M, Hornillos P, Soriano V, Enrĺquez J. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. J Viral Hepat 2008;15:392-8. [PMID: 18221300 DOI: 10.1111/j.1365-2893.2007.00966.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
558 Kallman JB, Tran S, Arsalla A, Haddad D, Stepanova M, Fang Y, Wrobel VJ, Srishord M, Younossi ZM. Vietnamese community screening for hepatitis B virus and hepatitis C virus. J Viral Hepat. 2011;18:70-76. [PMID: 20196807 DOI: 10.1111/j.1365-2893.2010.01278.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
559 Arai M, Togo S, Kanda T, Fujiwara K, Imazeki F, Yokosuka O. Quantification of hepatitis B surface antigen can help predict spontaneous hepatitis B surface antigen seroclearance. Eur J Gastroenterol Hepatol. 2012;24:414-418. [PMID: 22273987 DOI: 10.1097/meg.0b013e328350594d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
560 Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology. 2008;48:1070-1078. [PMID: 18688879 DOI: 10.1002/hep.22476] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 4.7] [Reference Citation Analysis]
561 Cheng Z, Lin P, Cheng N. HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases. Front Med (Lausanne) 2021;8:713981. [PMID: 34676223 DOI: 10.3389/fmed.2021.713981] [Reference Citation Analysis]
562 Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009;49:S129-37. [PMID: 19399799 DOI: 10.1002/hep.22931] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
563 Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, Teshima T. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 2015; 7(21): 2344-2351 [PMID: 26413224 DOI: 10.4254/wjh.v7.i21.2344] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
564 Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 2010;25:1374-80. [PMID: 20659226 DOI: 10.1111/j.1440-1746.2010.06381.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
565 Pan JS, Wang XZ, Ren JL. Long-term RNA interference and its application to hepatitis B virus. J Dig Dis 2009;10:165-71. [PMID: 19659783 DOI: 10.1111/j.1751-2980.2009.00381.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
566 Lee IC, Huang YH, Chu CJ, Lee PC, Lin HC, Lee SD. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. J Chin Med Assoc. 2010;73:156-160. [PMID: 20231001 DOI: 10.1016/s1726-4901(10)70031-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
567 Goulis I, Dalekos GN. Entecavir monotherapy for lamivudine-refractory chronic hepatitis B. Expert Rev Anti Infect Ther 2008;6:855-9. [PMID: 19053898 DOI: 10.1586/14787210.6.6.855] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
568 Han K, Kim DY. Chronic HBV infection with persistently normal ALT b. not to treat. Hepatol Int 2008;2:185-9. [DOI: 10.1007/s12072-008-9068-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
569 Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag 2009;5:789-98. [PMID: 19851526 DOI: 10.2147/tcrm.s5318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
570 Marinaki S, Kolovou K, Sakellariou S, Boletis JN, Delladetsima IK. Hepatitis B in renal transplant patients. World J Hepatol 2017; 9(25): 1054-1063 [PMID: 28951777 DOI: 10.4254/wjh.v9.i25.1054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
571 Woo HY, Choi JY, Yoon SK, Suh DJ, Paik SW, Han KH, Um SH, Kim BI, Lee HJ, Cho M, Lee CK, Kim DJ, Hwang JS. Rescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virus. Clin Mol Hepatol 2014;20:168-76. [PMID: 25032183 DOI: 10.3350/cmh.2014.20.2.168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
572 Kamat SP, Mehta PR, Paranjpe SM, Ingole NA. Hepatitis B Virus (HBV) Infection in Liver Disease Patients in Mumbai, India with Special Reference to Hepatitis B Surface Antigen (HBsAg) Mutant Detection. J Clin Diagn Res 2014;8:19-21. [PMID: 24783069 DOI: 10.7860/JCDR/2014/7202.4093] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
573 Sumer S, Aktug Demir N, Kölgelier S, Cagkan Inkaya A, Arpaci A, Saltuk Demir L, Ural O. The Clinical Significance of Serum Apoptotic Cytokeratin 18 Neoepitope M30 (CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels in Chronic Hepatitis B Patients with Cirrhosis. Hepat Mon. 2013;13:e10106. [PMID: 24032040 DOI: 10.5812/hepatmon.10106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
574 Drazilova S, Janicko M, Kristian P, Schreter I, Kucinsky B, Kozlej M, Hockickova I, Jarcuska P. Lower Viral Response to Pegylated Interferon Alpha 2a Treatment of Chronic Hepatitis B in Roma People in Eastern Slovakia. Gastroenterol Res Pract 2016;2016:8682494. [PMID: 26858755 DOI: 10.1155/2016/8682494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
575 Sampedro B, Hernández-López C, Ferrandiz JR, Illaro A, Fábrega E, Cuadrado A, Iruzubieta P, Menéndez S, Cabezas J, Crespo J. Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project. Hepatology. 2014;60:106-113. [PMID: 24585503 DOI: 10.1002/hep.27103] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
576 Suh HJ, Park MK, Lee HIe, Gwak GY, Koh KC, Paik SW, Yoo BC, Lee JH. [Antiviral efficacy of lamivudine/adefovir combination therapy in chronic hepatitis b patients with resistance to lamivudine and adefovir consecutively]. Korean J Gastroenterol 2009;53:305-10. [PMID: 19458467 DOI: 10.4166/kjg.2009.53.5.305] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
577 Wang JY, Mao RC, Zhang YM, Zhang YJ, Liu HY, Qin YL, Lu MJ, Zhang JM. Serum microRNA-124 is a novel biomarker for liver necroinflammation in patients with chronic hepatitis B virus infection. J Viral Hepat. 2015;22:128-136. [PMID: 25131617 DOI: 10.1111/jvh.12284] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
578 Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol. 2009;104:1693-1699. [PMID: 19455130 DOI: 10.1038/ajg.2009.187] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 4.7] [Reference Citation Analysis]
579 He J, Chen X, Sun J. Oral Wounds and Hepatitis B Virus Transmission. Infect Control Hosp Epidemiol 2014;35:1079-80. [DOI: 10.1086/677171] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
580 Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther. 2012;35:1326-1335. [PMID: 22506552 DOI: 10.1111/j.1365-2036.2012.05098.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
581 Hadziyannis E, Vassilopoulos D, Hadziyannis SJ. Quantitative HBsAg titer as predictor of response to therapy. Curr hepatitis rep 2009;8:169-72. [DOI: 10.1007/s11901-009-0024-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
582 Godon O, Fontaine H, Kahi S, Meritet JF, Scott-Algara D, Pol S, Michel ML, Bourgine M; ANRS HB02 study group. Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues. Mol Ther 2014;22:675-84. [PMID: 24394187 DOI: 10.1038/mt.2013.274] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
583 Tong MJ, Hsu L, Chang PW, Blatt LM. Evaluation of current treatment recommendations for chronic hepatitis B: A 2011 update: Treatment guidelines for hepatitis B. Journal of Gastroenterology and Hepatology 2011;26:829-35. [DOI: 10.1111/j.1440-1746.2011.06623.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
584 Kim SH, Kim JW, Lee KL, Lee S, Koh SJ, Jeong JB, Kim BG. Hepatitis B Virus Infection Is Independently Associated With Advanced Colorectal Adenoma. Am J Med Sci 2018;356:141-6. [PMID: 30219156 DOI: 10.1016/j.amjms.2018.04.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
585 Wong GL, Wong VW, Choi PC, Chan AW, Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31:1095-1103. [PMID: 20180785 DOI: 10.1111/j.1365-2036.2010.04276.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 84] [Article Influence: 7.3] [Reference Citation Analysis]
586 Tu HAT, Bos JH, Woerdenbag HJ, Visser ST, Wilschut JC, van Assen S, de Jong-van den Berg LT, Postma MJ. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the Northern Netherlands between 2000 and 2006. Clinical Therapeutics 2010;32:133-44. [DOI: 10.1016/j.clinthera.2010.01.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
587 Lee SH, Kim HS, Park KO, Park JW, Chun SY, Lim SJ, Cho HJ, Kim SJ, Park HW, Moon HK, Shin WG, Kim KH, Jang MK, Lee JH, Kim HY. Prevalence of IgG anti-HAV in patients with chronic hepatitis B and in the general healthy population in Korea. Korean J Hepatol 2010;16:362-8. [PMID: 21415579 DOI: 10.3350/kjhep.2010.16.4.362] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
588 Yin J, Xie J, Liu S, Zhang H, Han L, Lu W, Shen Q, Xu G, Dong H, Shen J. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol. 2011;106:81-92. [PMID: 20959817 DOI: 10.1038/ajg.2010.399] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 7.6] [Reference Citation Analysis]
589 Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki JP, Peyrin-Biroulet L. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol. 2009;33:1082-1093. [PMID: 19896313 DOI: 10.1016/j.gcb.2009.03.021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
590 Seiskari T, Lehtisaari H, Haapala AM, Aittoniemi J. From Abbott ARCHITECT anti-HBc to Anti-HBc II--improved performance in detecting antibodies to hepatitis B core antigen. J Clin Virol 2010;47:100-1. [PMID: 19962345 DOI: 10.1016/j.jcv.2009.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
591 Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat. 2007;14 Suppl 1:37-44. [PMID: 17958641 DOI: 10.1111/j.1365-2893.2007.00916.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
592 Xia L, Tian D, Huang W, Zhu H, Wang J, Zhang Y, Hu H, Nie Y, Fan D, Wu K. Upregulation of IL-23 expression in patients with chronic hepatitis B is mediated by the HBx/ERK/NF-κB pathway. J Immunol 2012;188:753-64. [PMID: 22174449 DOI: 10.4049/jimmunol.1101652] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
593 López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: Role of antiviral prophylaxis. World J Gastroenterol 2013; 19(9): 1342-1348 [PMID: 23538480 DOI: 10.3748/wjg.v19.i9.1342] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
594 Idilman R, Bozkus Y, Seval G, Mizrak D, Cinar K, Ustun Y, Bektas M, Arat M, Akbulut H, Doganay B, Ozden A. Lymphoproliferative disorders in individuals with chronic hepatitis B and C in the Turkish population. J Med Virol 2011;83:974-80. [PMID: 21503909 DOI: 10.1002/jmv.21747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
595 Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther. 2011;34:344-352. [PMID: 21671967 DOI: 10.1111/j.1365-2036.2011.04738.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 8.3] [Reference Citation Analysis]
596 Di Paolo D, Lenci I, Cerocchi C, Tariciotti L, Monaco A, Brega A, Lotti L, Tisone G, Angelico M. One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl Int. 2010;23:1105-1112. [PMID: 20492620 DOI: 10.1111/j.1432-2277.2010.01104.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
597 Badawi MM, Mohammed AA, Mohammed MS, Saeed MM, Ali EY, Khalil A. A Diagnostic Laboratory-Based Study on Frequency and Distribution of Viral Hepatitis B and C Among Sudanese. Open Virol J. 2017;11:98-107. [PMID: 29399232 DOI: 10.2174/1874357901711010098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
598 Zhang K, Cao H, Liang J, Shu X, Sun H, Li G, Xu Q. CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study. Medicine (Baltimore). 2016;95:e4471. [PMID: 27495085 DOI: 10.1097/md.0000000000004471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
599 Chang PE, Lui HF, Chau YP, Lim KH, Yap WM, Tan CK, Chow WC. Prospective evaluation of transient elastography for the diagnosis of hepatic fibrosis in Asians: comparison with liver biopsy and aspartate transaminase platelet ratio index. Aliment Pharmacol Ther. 2008;28:51-61. [PMID: 18410556 DOI: 10.1111/j.1365-2036.2008.03711.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.5] [Reference Citation Analysis]
600 Brunetto MR, Colombatto P, Bonino F. Personalized therapy in chronic viral hepatitis. Mol Aspects Med 2008;29:103-11. [PMID: 18068759 DOI: 10.1016/j.mam.2007.09.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
601 Dufour DR. Liver Disease. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier; 2012. pp. 1637-93. [DOI: 10.1016/b978-1-4160-6164-9.00050-0] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
602 Drazilova S, Janicko M, Kristian P, Schreter I, Halanova M, Urbancikova I, Madarasova-Geckova A, Marekova M, Pella D, Jarcuska P; HepaMeta Team. Prevalence and Risk Factors for Hepatitis B Virus Infection in Roma and Non-Roma People in Slovakia. Int J Environ Res Public Health. 2018;15:1047. [PMID: 29789486 DOI: 10.3390/ijerph15051047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
603 Xing TJ, Xu HT, Yu WQ, Wang B, Zhang J. MiRNA-548ah, a potential molecule associated with transition from immune tolerance to immune activation of chronic hepatitis B. Int J Mol Sci. 2014;15:14411-14426. [PMID: 25196343 DOI: 10.3390/ijms150814411] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
604 Ferrante ND, Lo Re V 3rd. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection. Curr HIV/AIDS Rep. 2020;17:405-414. [PMID: 32607773 DOI: 10.1007/s11904-020-00508-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
605 Guo X, Yang G, Yuan J, Ruan P, Zhang M, Chen X, Zhou B. Genetic variation in interleukin 28B and response to antiviral therapy in patients with dual chronic infection with hepatitis B and C viruses. PLoS One. 2013;8:e77911. [PMID: 24147097 DOI: 10.1371/journal.pone.0077911] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
606 Li L, Li B, Zhang M. HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion. Medicine (Baltimore) 2019;98:e16308. [PMID: 31277172 DOI: 10.1097/MD.0000000000016308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
607 Ke WM, Xie SB, Li XJ, Zhang SQ, Lai J, Ye YN, Gao ZL, Chen PJ. There were no differences in serum HBV DNA level between HBeAg-positive and HBeAg-negative chronic hepatitis B with same liver histological necroinflammation grade but differences among grades 1, 2, 3 and 4 apportioned by the same hepatic parenchyma cell volume. J Viral Hepat. 2011;18:637-645. [PMID: 21794025 DOI: 10.1111/j.1365-2893.2011.01444.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
608 Gong MM, Macdonald BD, Vu Nguyen T, Van Nguyen K, Sinton D. Field tested milliliter-scale blood filtration device for point-of-care applications. Biomicrofluidics 2013;7:44111. [PMID: 24404044 DOI: 10.1063/1.4817792] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
609 Chan HL, Wong GL, Tse CH, Chan HY, Wong VW. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis. 2011;204:408-414. [PMID: 21742839 DOI: 10.1093/infdis/jir283] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 7.1] [Reference Citation Analysis]
610 Tabernero D, Sánchez MJ, Homs M, Rodríguez-frías F, Jardí R, Schaper M, Esteban R, Buti M. Main mutations in the hepatitis B virus basic core promoter (A1762T/G1764A) before HBeAg loss are markers that identify patients who will require long-term treatment: Hepatitis B mutations and therapy response. Alimentary Pharmacology & Therapeutics 2010;32:97-104. [DOI: 10.1111/j.1365-2036.2010.04319.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
611 Chen Y, Zhao Z, Fan H, Li Z, He Y, Liu C. Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial. Contemp Clin Trials Commun 2020;19:100601. [PMID: 32642592 DOI: 10.1016/j.conctc.2020.100601] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
612 Chen X, Cao Z, Liu Y, Zhang H, Zhang Y, Ma L, Jin Y, Yu H, Ma B, Zheng Y, Wu H. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. J Gastroenterol Hepatol 2012;27:481-6. [PMID: 22098411 DOI: 10.1111/j.1440-1746.2011.06970.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
613 Wu I, Shiffman M, Tong M, Marcellin P, Mondou E, Frederick D, Snow‐lampart A, Sorbel J, Rousseau F, Chang T. Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants. CLIN INFECT DIS 2008;47:1305-11. [DOI: 10.1086/592570] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
614 Wang L, Yao M, Liu S, Yang D, Wen X, Ning J, Wang L, Zhou G, Xu Q, Chen X, Zhao J, Lu F. Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. Dis Markers 2020;2020:6036904. [PMID: 32089754 DOI: 10.1155/2020/6036904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
615 Almeida AM, Ribeiro AQ, Pádua CA, Brandão CM, Andrade EI, Cherchiglia ML, Carmo RA, Acurcio Fde A. [The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review]. Rev Soc Bras Med Trop 2010;43:440-51. [PMID: 20802947 DOI: 10.1590/s0037-86822010000400021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
616 Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. J Hepatol. 2010;52:791-799. [PMID: 20409606 DOI: 10.1016/j.jhep.2009.12.036] [Cited by in Crossref: 87] [Cited by in F6Publishing: 88] [Article Influence: 7.3] [Reference Citation Analysis]
617 Chen L, Zhang Q, Yu DM, Wan MB, Zhang XX. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy. J Hepatol. 2009;50:895-905. [PMID: 19304333 DOI: 10.1016/j.jhep.2008.12.018] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
618 Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci. 2015;60:3465-3472. [PMID: 26138653 DOI: 10.1007/s10620-015-3775-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
619 Yang J, Zhao LS. Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report. Virol J 2009;6:97. [PMID: 19583877 DOI: 10.1186/1743-422X-6-97] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
620 Ozaras R, Inanc Balkan I, Yemisen M, Tabak F. Epidemiology of HBV subgenotypes D. Clin Res Hepatol Gastroenterol. 2015;39:28-37. [PMID: 25037178 DOI: 10.1016/j.clinre.2014.06.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
621 Wang K, Liu H, He Y, Chen T, Yang Y, Niu Y, Chen H, Chen Y, Liu J, Ye F, Lin S, Zhao Y. Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Human Immunology 2010;71:950-6. [DOI: 10.1016/j.humimm.2010.07.013] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
622 Ozaras R, Corti G, Ruta S, Lacombe K, Mondelli M, Irwing W, Puoti M, Khalighi A, Santos M, Harxhi A, Lazarevic I, Soriano V, Gervain J, Leblebicioglu H, Salmon D, Arends J. Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. Clinical Microbiology and Infection 2015;21:1027-32. [DOI: 10.1016/j.cmi.2015.07.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
623 Hu Z, Li M, Liu J, Yu L, Xue Y, Chen Y. Detection of Hepatitis B Virus Large Surface Protein Using a Time-Resolved Immunofluorometric Assay. J Clin Lab Anal 2015;29:498-504. [PMID: 25277704 DOI: 10.1002/jcla.21800] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
624 Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.Nat Rev Clin Oncol. 2012;9:156-166. [PMID: 22271089 DOI: 10.1038/nrclinonc.2012.1] [Cited by in Crossref: 107] [Cited by in F6Publishing: 90] [Article Influence: 10.7] [Reference Citation Analysis]
625 Floret N, Cervoni J, Sheppard F, Des Floris ML, Duchêne F. Immunosuppression-mediated hepatitis B reactivation diagnosed following an investigation into suspected transfusion-transmitted hepatitis B. Journal of Hospital Infection 2013;83:244-6. [DOI: 10.1016/j.jhin.2012.11.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
626 Weldemhret L, Asmelash T, Belodu R, Gebreegziabiher D. Sero-prevalence of HBV and associated risk factors among HIV positive individuals attending ART clinic at Mekelle hospital, Tigray, Northern Ethiopia. AIDS Res Ther 2016;13:6. [PMID: 26855663 DOI: 10.1186/s12981-016-0090-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
627 Jafri SR, Lok AS. Antiviral Therapy for Chronic Hepatitis B. Clinics in Liver Disease 2010;14:425-38. [DOI: 10.1016/j.cld.2010.05.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
628 Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH. Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2018;70:724-731. [PMID: 28834412 DOI: 10.1002/acr.23346] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
629 Yap DYH, Chan TM. Evolution of hepatitis B management in kidney transplantation. World J Gastroenterol 2014; 20(2): 468-474 [PMID: 24574715 DOI: 10.3748/wjg.v20.i2.468] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
630 Marcellin P, Sung J, Piratvisuth T. Avoiding and managing lamivudine resistance in chronic hepatitis B: current approaches and potential strategies including pegylated interferon. Liver International 2010;30:657-68. [DOI: 10.1111/j.1478-3231.2010.02207.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
631 Xia B, Wang F, Friedrich-Rust M, Zhou F, Zhu J, Yang H, Ruan W, Zeng Z. Feasibility and Efficacy of Transient Elastography using the XL probe to diagnose liver fibrosis and cirrhosis: A meta-analysis. Medicine (Baltimore) 2018;97:e11816. [PMID: 30278481 DOI: 10.1097/MD.0000000000011816] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
632 Liu T, Yao M, Liu S, Wang L, Wang L, Hou J, Ma X, Jia J, Zhao J, Zhuang H, Lu F. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget. 2017;8:16498-16506. [PMID: 28157705 DOI: 10.18632/oncotarget.14954] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
633 Cui XJ, Cho YK, Song BC. Influence of the basal core promoter and precore mutation on replication of hepatitis B virus and antiviral susceptibility of different genotypes. J Med Virol 2015;87:601-8. [PMID: 25612255 DOI: 10.1002/jmv.24117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
634 Fujimoto Y, Hashimoto N, Kinoshita M, Miyazaki Y, Tanaka S, Yakushijin T, Takehara T, Kagawa N, Yoshimine T. Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. Int J Clin Oncol 2012;17:290-3. [PMID: 21809177 DOI: 10.1007/s10147-011-0294-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
635 Poupardin C, Nahon S, Pariente A, Cadranel JF, Renou C. Hepatitis B reactivation in patients with inflammatory bowel disease: A prospective survey on screening and prevention practices at general hospitals in France. Inflamm Bowel Dis. 2011;17:669-670. [PMID: 20848488 DOI: 10.1002/ibd.21276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
636 Yurdaydin C. Entecavir: a step forward in combating hepatitis B disease. Expert Opinion on Pharmacotherapy 2008;9:3095-109. [DOI: 10.1517/14656560802515546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
637 Leung C, Tsoi E, Burns G, Sievert W. An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening. Oncologist 2011;16:579-84. [PMID: 21464465 DOI: 10.1634/theoncologist.2010-0182] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
638 Adelakun AA, Adediji IO, Idowu OJ, Jegede TF, Oluremi AS, Adepoju PO, Olaniyan OA. Prognostic significance of serum telomerase activity in the monitoring of hepatitis B viral infection. J Immunoassay Immunochem 2021;:1-9. [PMID: 34861808 DOI: 10.1080/15321819.2021.2004162] [Reference Citation Analysis]
639 Mao QG, Pan JS, Fang KN, Zhang RM, Hong QY, Song MN, Zhu JP, Huang WQ, Chen LM, Hong MZ. Precise prediction model and simplified scoring system for sustained combined response to interferon-α. World J Gastroenterol 2010; 16(27): 3465-3471 [PMID: 20632453 DOI: 10.3748/wjg.v16.i27.3465] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
640 Yan JY, Li ZQ, Yu ZJ, Kan QC. Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels. J Cell Biochem 2019;120:6632-41. [PMID: 30368885 DOI: 10.1002/jcb.27959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
641 Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Chen CJ. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921-931. [PMID: 17678844 DOI: 10.1016/j.cgh.2007.06.015] [Cited by in Crossref: 152] [Cited by in F6Publishing: 139] [Article Influence: 10.1] [Reference Citation Analysis]
642 Nishijima N, Marusawa H, Ueda Y, Takahashi K, Nasu A, Osaki Y, Kou T, Yazumi S, Fujiwara T, Tsuchiya S. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One. 2012;7:e35052. [PMID: 22523569 DOI: 10.1371/journal.pone.0035052] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.0] [Reference Citation Analysis]
643 Choi YJ, Kim HS, Lee SH, Park JS, Nam HS, Kim HJ, Kim CJ, Jeong DJ, Park KS, Baek KA. Evaluation of peptide nucleic acid array for the detection of hepatitis B virus mutations associated with antiviral resistance. Arch Virol 2011;156:1517-24. [PMID: 21594598 DOI: 10.1007/s00705-011-1019-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
644 Van Damme P, Ward JW, Shouval D, Zanetti A. Hepatitis B Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 342-374.e17. [DOI: 10.1016/b978-0-323-35761-6.00025-0] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
645 Di Marco V, Craxì A. Chronic hepatitis B: who to treat and which choice of treatment? Expert Rev Anti Infect Ther 2009;7:281-91. [PMID: 19344242 DOI: 10.1586/eri.09.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
646 European Association For The Study Of The Liver. [EASL clinical practice guidelines. Management of chronic hepatitis B]. Gastroenterol Clin Biol. 2009;33:539-554. [PMID: 19481389 DOI: 10.1016/j.gcb.2009.03.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
647 Ueda Y, Marusawa H, Ichinohe T, Kadowaki N, Uchiyama T, Chiba T. Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies. Am J Hematol 2009;84:315-6. [PMID: 19350661 DOI: 10.1002/ajh.21388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
648 Gao Y, He J. More clinical guideline inconsistency regarding the prevention of hepatitis B and C virus transmission. Am J Infect Control 2016;44:1190-1. [PMID: 27324613 DOI: 10.1016/j.ajic.2016.03.061] [Reference Citation Analysis]
649 Tillmann HL. Screening for and Treating Hepatitis B Virus in Patients with HIV Infection. Clinical Infectious Diseases 2007;45:633-6. [DOI: 10.1086/520753] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
650 Zhou Y, Yan R, Ru GQ, Yu LL, Yao J, Wang H. Pegylated-interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non-cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open-label pilot trial. Hepatol Int. 2019;13:422-430. [PMID: 31172416 DOI: 10.1007/s12072-019-09957-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
651 Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis. 2008;8:167-178. [PMID: 18053766 DOI: 10.1016/s1473-3099(07)70264-5] [Cited by in Crossref: 138] [Cited by in F6Publishing: 55] [Article Influence: 9.2] [Reference Citation Analysis]
652 Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int. 2013;33:244-254. [PMID: 23295056 DOI: 10.1111/liv.12036] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
653 Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatology. 2009;49:S35-S44. [PMID: 19399812 DOI: 10.1002/hep.22882] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 8.1] [Reference Citation Analysis]
654 Togo S, Arai M, Tawada A, Chiba T, Kanda T, Fujiwara K, Imazeki F, Yokosuka O. Clinical importance of serum hepatitis B surface antigen levels in chronic hepatitis B: Quantitative serology for HbsAg. Journal of Viral Hepatitis 2011;18:e508-15. [DOI: 10.1111/j.1365-2893.2011.01486.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
655 Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2008;26:937-49. [PMID: 18850763 DOI: 10.2165/00019053-200826110-00006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
656 Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther 2014;40:804-10. [PMID: 25109610 DOI: 10.1111/apt.12908] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
657 Taida T, Arai M, Kanda T, Hige S, Ueno Y, Imazeki F, Izumi N, Tanaka E, Shinkai N, Yoshioka K, Nakamoto Y, Nishiguchi S, Tsuge M, Abe M, Sata M, Yatsuhashi H, Ido A, Kita K, Azemoto R, Kitsukawa Y, Goto N, Yokosuka O. The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study. J Gastroenterol 2017;52:113-22. [PMID: 27306374 DOI: 10.1007/s00535-016-1229-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
658 Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J, Cooper DA, Bowden S. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology. 2008;48:1062-1069. [PMID: 18697216 DOI: 10.1002/hep.22462] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 6.8] [Reference Citation Analysis]
659 Vallet-Pichard A, Mallet V, Costentin CE, Pol S. Treatment of HBV-related cirrhosis. Expert Rev Anti Infect Ther. 2009;7:527-535. [PMID: 19485793 DOI: 10.1586/eri.09.28] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
660 Diktas H, Karacaer Z, Özturk II, Cicek H. Comparison of relationship between histopathological, serological and biochemical parameters in patients with chronic hepatitis B infection. Postgrad Med J 2016;92:693-6. [PMID: 27170311 DOI: 10.1136/postgradmedj-2016-134069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
661 Kim SR, Yang J, Kudo M, Hino O. Recent advances in the management of chronic hepatitis B. Hepat Mon 2011;11:601-11. [PMID: 22140383 DOI: 10.5812/kowsar.1735143x.657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
662 Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008;48:99-108. [PMID: 18537189 DOI: 10.1002/hep.22323] [Cited by in Crossref: 122] [Cited by in F6Publishing: 110] [Article Influence: 8.7] [Reference Citation Analysis]
663 Bacon BR. Workforce issues in hepatology: What is needed? Hepatology 2008;47:1801-4. [DOI: 10.1002/hep.22276] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
664 Lee H, Park W. Public Health Policy for Management of Hepatitis B Virus Infection: Historical Review of Recommendations for Immunization. Public Health Nursing 2010;27:148-57. [DOI: 10.1111/j.1525-1446.2010.00842.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
665 Tsutsumi Y, Ogasawara R, Kamihara Y, Ito S, Yamamoto Y, Tanaka J, Asaka M, Imamura M. Rituximab administration and reactivation of HBV. Hepat Res Treat 2010;2010:182067. [PMID: 21188195 DOI: 10.1155/2010/182067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
666 Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17(12): 1531-1537 [PMID: 21472116 DOI: 10.3748/wjg.v17.i12.1531] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 56] [Article Influence: 5.1] [Reference Citation Analysis]
667 Li X, Li F, Zhang Y, Kang Y, Yu J, Yang F, Liu H, Qin Y, Huang Y, Mao R, Zhang J. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity. Biochem Biophys Res Commun 2015;464:1185-91. [PMID: 26212437 DOI: 10.1016/j.bbrc.2015.07.101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
668 Marugán RB, Garzón SG. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J Gastroenterol 2009; 15(4): 423-430 [PMID: 19152446 DOI: 10.3748/wjg.15.423] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
669 Fonseca JC. Natural history of chronic hepatitis B. Rev Soc Bras Med Trop. 2007;40:672-677. [PMID: 18200423 DOI: 10.1590/S0037-86822007000600015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
670 Shen T, Yan XM. Hepatitis B virus genetic mutations and evolution in liver diseases. World J Gastroenterol 2014; 20(18): 5435-5441 [PMID: 24833874 DOI: 10.3748/wjg.v20.i18.5435] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
671 Aziz M, Aziz H, Waheed Y, Gill ML. Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. Viral Immunol 2018;31:632-8. [PMID: 30285571 DOI: 10.1089/vim.2018.0022] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
672 Dinney CM, Zhao LD, Conrad CD, Duker JM, Karas RO, Hu Z, Hamilton MA, Gillis TR, Parker TM, Fan B. Regulation of HBV-specific CD8(+) T cell-mediated inflammation is diversified in different clinical presentations of HBV infection. J Microbiol. 2015;53:718-724. [PMID: 26428923 DOI: 10.1007/s12275-015-5314-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
673 Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy: HBcrAg is a predictor of HCC recurrence. Liver International 2010;30:1461-70. [DOI: 10.1111/j.1478-3231.2010.02344.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
674 Cha CK, Kwon HC, Cheong JY, Cho SW, Hong SP, Kim SO, Yoo WD. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B. J Med Virol 2009;81:417-24. [PMID: 19152409 DOI: 10.1002/jmv.21402] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
675 Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010;30:512-520. [PMID: 20102511 DOI: 10.1111/j.1478-3231.2009.02198.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
676 Lee KS, Kim DJ; Guideline Committee of the Korean Association for the Study of the Liver. Management of Chronic Hepatitis B. Korean J Hepatol 2007